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Abstract  
Advanced breast carcinoma is a main cause of mortality affecting women. It is associated 
with poor prognosis; therefore, understanding the molecular mechanisms of invasive 
malignancies is critical in order to discover new therapies and to optimise current therapies. 
Degradation of the Extracellular Matrix (ECM) is a crucial step in tumour growth and 
invasion, allowing the cancerous cells to metastasize to distant organs and form secondary 
tumours. Matrix metalloproteinases (MMP) are a family of zinc-dependant endopeptidases 
that have the capability to degrade the ECM, enabling tumours cells to invade and migrate. 
Hence, MMP overexpression and/or enhanced activity are positively associated with breast 
cancer metastasis and invasion. Two MMPs have been shown to be involved in breast 
cancers, gelatinase A (MMP-2) and gelatinase B (MMP-9). The activity of MMPs is tightly 
regulated by endogenous inhibitors that are called tissue inhibitors of metalloproteinases 
(TIMPs). There are four different endogenous negative regulator proteins of MMPs, with 
TIMP-1 and TIMP-2 inhibiting MMP-9 and -2, respectively. Due to their potential role in 
tumour metastasis, a great interest has grown in developing novel methods to inhibit the 
MMPs as there is a direct relation between the expression of MMPs and the invasiveness of 
the tumours. The Farnesoid X Receptor (FXR) is a nuclear receptor that is highly expressed 
in breast cancers, and has been reported to be involved in in regulation of MMP and TIMP 
activity in hepatic and vascular tissues. The rationale of the current study was to investigate 
whether FXR is a novel regulator of matrix metalloprotease-2 and -9 in metastatic breast 
cancer cells, and hence may represent a novel therapeutic target. Two FXR agonists were 
used to measure their effects on breast cancer cells MDA-MB-231, MDA-MB-468 (triple 
negative), MCF-7 (Estrogen receptor positive) and normal cells MCF10A: chenodeoxycholic 
acid (CDCA) is an endogenous (low-affinity, low-selectivity) ligand, while 3-[2-[2-Chloro-4-
[[3-(2, 6-dichlorophenyl)-5-(1-methylethyl)-4isoxazolyl]methoxy]phenyl]ethenyl]benzoic 
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acid  (GW4064) is a synthetic (high affinity, high-selectivity) ligand. Cell viability, protein 
and mRNA levels of matrix metalloprotease -2 and -9 and TIMP-2 and -1, and cell migration 
were assessed using both molecular and cellular techniques. Both FXR agonists decreased 
breast cancer and normal breast cell viability, with the effects more significant in the triple 
negative cells, suggesting a potential targeting towards aggressive, hard-to-treat cancer cell-
types. However, the FXR ligands didn’t alter mRNA and protein levels of MMP-2, MMP-9, 
TIMP-1 and TIMP-2 intracellularlly or extracellularlly, suggesting that this cytotoxic effect 
may not be via MMP. FXR ligands also had no effect on breast cancer cell migration, which 
is consistent with the suggestion that FXR activation has a general cytotoxic effect on tumour 
cells, but does not directly impact on tumour migration. In conclusion, FXR activation does 
not impact on markers of breast cancer metastasis, suggesting that its potential as a 
therapeutic target to prevent tumour progression may be limited. However, the cytotoxic 
effect on cancer cells is promising, suggesting that these agonists may still possess some 
potential for breast cancer therapy.  
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1 General Introduction 
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 Overview of breast cancer  
Breast cancer is the most common cancer to affect women in nearly all countries (Cardoso et 
al., 2012). It remains a leading cause of cancer death in women aged 20–59 years despite 
significant advances in decreasing mortality that have occurred since the 1990s (Jemal et al., 
2009, Dawson et al., 2013). A major reason for limited success in reducing breast cancer 
mortality is the inherent variability in the molecular signatures underlying breast cancer. 
Indeed, breast cancer may be better viewed as a group of heterogeneous diseases that simply 
occur in a single organ of the body. The different breast cancer sub-types display significant 
differences in their molecular and clinical behaviour, and patient stratification and 
personalisation of treatment is one of the hardest challenges that faces clinicians and 
researchers (Dawson et al., 2013). An important aspect of breast cancer heterogeneity is the 
potential for tumours to invade surrounding tissue and migrate to distant sites in the body 
(metastasis), which has a major negative impact on patient prognosis (Prat and Perou, 2011, 
Rouzier et al., 2005).  
These differences in clinical characteristics of breast cancers are driven by heterogeneity in 
molecular landscape; however, this heterogeneity often results in histologically similar 
tumours, meaning that tumour classification by this method is limited. To this end, a number 
of molecular breast cancer classification systems have been suggested, usually relying on 
DNA microarray technology (Rouzier et al., 2005, Perou et al., 2000). Despite this, the link 
between breast cancer subtypes, whether histological or molecular, and patient prognosis is 
still unclear. There is thus an imperative to gain a more detailed mechanistic understanding of 
breast cancer, to drive improved patient stratification and effective treatment, as well as the 
design of novel therapeutic agents. 
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1.1.1 Risk factors for breast cancer  
Breast carcinoma is a multifactorial, complex disease, with a strong interaction between 
genetic and environmental factors contributing to the development and behaviour of 
individual tumours (Martin and Weber, 2000).  
Breast cancer incidence increases with the age, with 80% of breast cancer cases diagnosed in 
the over 50s and 24% in women at the age of 75 and above (CancerResearchUK). 
After age, a positive family history of breast cancer is the most important risk factor for 
developing the disease (Claus et al., 1994, Claus et al., 1998). However, it is important to put 
this in context, with inherited breast carcinoma thought to account for only 5-10 % of all 
breast cancers (Ford and Easton, 1995, Martin and Weber, 2000, O'Donovan and Livingston, 
2010). BRCA1 and BRCA2 are the most important susceptibility genes so far identified 
(Martin and Weber, 2000, Thompson and Easton, 2004). BRCA1 and BRCA2 act as tumour 
suppressor genes (O'Donovan and Livingston, 2010), with mutations in these genes 
responsible for high lifetime risk of both breast cancer and ovarian cancer (Thompson and 
Easton, 2004). 
Prolonged exposure to estrogen has also been linked to an increased risk of breast cancer 
(Begg et al., 1987, Pike et al., 1979), with a reduction in exposure protective (Hulka, 1997). 
As such, the probability of developing the breast cancer may also be related to the number of 
menstrual cycles in an individual, with the breast cancer risk associated with early menarche 
(decreased risk), late menopause (increased risk) and nulliparity (increased risk) 
(Trichopoulos et al., 1972, White, 1987, Kampert et al., 1988, McPherson et al., 2000, 
Newcomb et al., 2011). Furthermore, it has been reported that hormone replacement therapy 
(HRT) is also a risk factor for developing breast cancer; the increase in risk is not high, but it 
increases with long-term usage (Agarwal and Judd, 1999). For example, Li et al. reported that 
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in middle aged women, use of the combined estrogen and progestin hormone replacement 
therapy  increased the risk of lobular breast carcinoma (OR 2.6; 95% CI 1.1-5.8), but  not 
ductal cancer (Li et al., 2000). Finally, as the major endogenous source of estrogen is the 
conversion of androstenedione to estrone in adipose tissue in postmenopausal women, a link 
between obesity and increased risk of breast cancer has been reported (Martin and Weber, 
2000, Pujol et al., 1997, Harvie et al., 2003, Ligibel, 2011).  
In addition to the established risk factors of estrogen levels and genetic status, there are two, 
more general, risk factors that have been associated with an increased risk of breast cancer: 
First, a number of studies have reported that both the quantity and period of alcohol 
consumption are positively related to an increased breast cancer risk (Bowlin et al., 1997, 
Rohan et al., 2000, Ewertz, 1991, Garfinkel et al., 1988). Second, dietary factors been 
associated with increased breast cancer risk, including a high dietary fat intake, and the 
ingestion of the pyrolysis products through the flame cooking of meat products (Zheng et al., 
1999, Zheng et al., 1998, Boyd et al., 1993).  
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1.1.2 Classification of breast cancer 
1.1.2.1 Histopathological subtypes 
As detailed in the general introduction, breast cancers were originally classified through 
histology, and this remains a common practice today. Breast carcinomas are divided mainly 
into Invasive ductal carcinoma (IDC) and Invasive lobular carcinoma (ILC) based on 
architectural and cytological characteristics (Dawson et al., 2013, Korkola et al., 2003). These 
two sub-types are the most common breast cancers, and account for 80% and 25% of all 
invasive breast tumours, respectively (Korkola et al., 2003, Dawson et al., 2013). The 
commonest non-invasive breast cancer is Ductal carcinoma in situ (DCIS), which accounts 
for nearly 12% of newly diagnosed breast cancers (Barclay et al., 1997).   
1.1.2.2 Molecular classification  
While the classification of breast tumours by histological methods provides a broad-brush 
approach, it does not always lead to the most effective therapeutic strategy being applied. 
This is mainly due to the heterogeneity within each of the histological classifications, such 
that several breast cancer phenotypes can exist within a single classification. To mitigate this 
problem, there has been a large body of work aimed at identifying molecular markers of 
breast cancer, which could be used independently of, or as a complement to, histological 
classification. The most established molecular classification system is based upon the 
expression of three receptors within breast tumours: the estrogen receptor (ER), the 
progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) 
(Dawson et al., 2013, Recareanu et al., 2011, Santagata et al., 2014). In general, expression of 
these receptors is associated with good patient prognosis and clear, targeted therapeutic 
options (see section1.1.3), while triple-negative breast cancers (TNBCs) are associated with 
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poor patient prognosis, being both the most aggressive and lacking specific therapeutics 
(Santagata et al., 2014, Sorlie et al., 2001, Sørlie et al., 2003).  
In addition to molecular studies aimed at identifying a single marker, global gene expression 
analysis of human breast cancers has been used to provide more comprehensive classification 
approaches. Using such techniques, several molecular subtypes of breast cancer have been 
proposed. These intrinsic subtypes include luminal A, luminal B, HER2-enriched, and basal-
like (Perou et al., 2000, Sorlie et al., 2001, Sørlie et al., 2003, Fan et al., 2006). Hormone 
receptors gene expression is a feature of luminal A, luminal B and HER2 sub-types, while the 
basal-like subtype is triple negative (and often referred to as triple negative breast cancer; 
TNBC). Both luminal A and B are positive for ER and PR expression, with HER2 expression 
being associated with luminal A, but not luminal B. The HER2 sub-type expresses HER2, but 
is ER and PR negative (Sorlie et al., 2001, Sørlie et al., 2003, Perou et al., 2000). 
An alternative molecular intrinsic subtype of breast carcinoma has been recently proposed, 
characterised by low expression of claudin; this subtype was identified using gene expression 
analyses in mouse tumours and breast cancer cell lines (Herschkowitz et al., 2007, Prat et al., 
2010). This subtype possesses a unique set of genetic alterations and responds to therapy in a 
different way (Rouzier et al., 2005, Troester et al., 2004). However, it is important to note 
that the extrapolation of this sub-type to the human situation has not been fully examined yet, 
which is an important factor in determining the potential of this molecular classifier. 
Beyond the use of ER, PR, and HER2 status, the most widely used molecular classification 
system is the PAM50 set, a group of 50 genes whose expression correlates with clinical 
outcome (Parker et al., 2009, Nielsen et al., 2010). This classification system has the 
advantage of using an expanded molecular classifier (50 target genes), which provides a 
larger discriminatory power compared to single predictors. 
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Perhaps the largest molecular classification of breast cancer was undertaken by METABRIC, 
a UK- and Canadian-funded study that examined genomic and transcriptomic data from 
2,000 breast tumours (Curtis et al., 2012). Importantly, this molecular information was 
coupled with standard histopathology screening and patient survival data. In this landmark 
study, the examined tumours could be divided into ten distinct molecular classifications that 
showed a correlation with patient survival and response to treatment. 
In summary, the era of systems biology has resulted in a number of novel molecular 
classifiers for breast cancer. However, the lack of concordance between studies, suggests that 
further work must be done to produce clinically significant, practical molecular classifiers 
(Gokmen-Polar and Badve, 2012). Hence, at the present time, breast cancer screening is still 
predominantly restricted to histological examination and use of ER, PR and HER2 receptor 
status.  
1.1.3 Treatment of breast cancer 
Treatment of breast cancer can be divided into two major approaches, namely local 
treatments and systemic treatments. In local therapy, the affected breast tissue and the 
neighbouring lymph nodes are treated by surgery and/or radiotherapy. In contrast, systemic 
treatment uses chemotherapy, including hormone treatment, to treat the entire body. While 
local treatments can be highly effective in removing the targeted tumour, they do not impact 
upon tumours at dispersed sites, such as occur through metastasis. In contrast, systemic 
treatments will treat both primary and secondary tumours, but with an increased risk of off-
target side effects. In practice, these approaches are often combined, with localised treatment 
used first to remove the primary tumour, followed by systemic chemotherapy to destroy 
secondary tumours (BreastCancer.Org). 
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At present, there are a number of adjuvant and neoadjuvant chemotherapeutic treatments 
commonly used for breast cancer. Adjuvant therapy refers to treatment that is used after the 
primary therapy, such as chemotherapy following surgery, whereas neoadjuvant therapy 
refers to treatment prior to the primary therapy. Table 1.1 presents some commonly used 
adjuvant and neoadjuvant therapies used in the treatment of breast cancer. Some of these 
treatments are targeted against particular molecular subtypes (e.g. Herceptin, tamoxifen), and 
hence specific to breast cancer, while others are more general cytotoxic approaches (e.g. 
paclitaxel), and hence applicable to several tumour types.  
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Table 1-1 Adjuvant and neoadjuvant chemotherapeutic treatment for breast cancer 
(CancerResearchUK) 
 
Chemotherapy and hormonal drugs Cancer type  
Cyclophosphamide (Alkylating agents) Breast cancer and other cancers like 
lymphomas, leukaemias, myeloma, lung. Used 
in a combination with other anti-cancer drugs 
or in a single high dose. 
Doxorubicin and Epirubicin (Antibiotic 
anthracyclines) 
Early-stage breast cancers and also many 
different such as ovarian cancer, stomach 
cancer, lung cancer, bowel cancer, myeloma. 
Used in a combination with other anti-cancer 
drugs. 
Cisplatin and Carboplatin (Platinum 
agents) 
Cisplatin is used to treat breast cancer, and 
also testicular, ovarian, bladder, head and 
neck, and non-small cell lung cancers. 
Carboplatin is used to treat advanced-stage 
breast cancer (metastatic breast cancer). 
Methotrexate (Anti metabolites) Early-stage breast cancer after surgery, and 
also used to treat advanced-stage breast 
cancer. It is used to treat other cancers such as 
lung, head and neck, ovarian, cervical, 
testicular cancers.  
5-fluorouracil (Anti metabolites)  Is used to treat different cancers including 
breast, head and neck, anal, stomach, colon 
and some skin cancers. It may be combined 
with other anti-cancer agents or with 
radiotherapy. 
Paclitaxel and Docetaxel (Taxanes)  
 
Paxlitaxel is used to treat breast, ovarian, lung, 
bladder, prostate, melanoma, esophageal 
cancers, also Kaposi's sarcoma. Sometimes 
used in a combination with other anti-cancer 
drugs. Docetaxel is used to treat breast, Lung, 
head and neck, prostate, stomach cancers. 
Tamoxifen and Aromatase inhibitors  Tamoxifen is used to treat ER+ breast cancer. 
Aromatase inhibitors used to treat ER+ breast 
cancer in post-menopausal women 
Trastuzumab (Herceptin)  It is used to treat HER2+ breast, cancer early 
and advanced stages.  
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1.1.4 Metastatic breast cancer  
A larger proportion of the deaths from breast cancer, and indeed many cancers, are associated 
with the metastasis of the primary tumour to other organs, and not from the primary tumour 
directly (Hunter et al., 2008, Mundy, 2002). Therefore, metastatic progression, may be 
considered the main cause of cancer death (Steeg, 2006), and hence the target for treatment. 
In breast cancer, only 20% of the patients will survive 5 years after the detection of 
metastasis (Coleman, 2001, Cardoso et al., 2012). Importantly, at diagnosis only 5% to 10% 
of breast cancers have metastasized, meaning that there is a window of opportunity for 
effective, targeted treatment. Such treatment must have the joint aims of destroying the 
primary tumour and preventing metastasis. 
The skeleton is most common site for breast carcinoma metastasis, with the bone 
environment providing the perfect microenvironment for development of secondary tumours; 
ample amounts of local cytokines and growth factors in the bone maybe the reason why 
breast tumour metastasize to the skeleton even though the exact reason is unknown 
(Hauschka et al., 1986, Mundy, 1997, Yoneda et al., 1994). Furthermore, blood flow in the 
red marrow is high (Kahn et al., 1994). Cancer cells express adhesive molecules that help 
them to bind to the stromal cells of marrow and to the bone matrix. This interaction between 
the tumour cells and the bone cells makes the tumour cells to produce angiogenic factors and 
bone resorbing factors that help tumour growth in bone more (van der Pluijm et al., 2001). It 
was reported that tumour and stromal matrix metalloproteinases (MMP) play a vital role in 
the metastatic spread of most breast carcinomas (Lochter and Bissell, 1999, MacDougall and 
Matrisian, 1995). 
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In breast cancer, 70% of patients suffer secondary bone tumours (Body, 1995, Coleman and 
Rubens, 1987, Mundy, 1997). Metastasis to the bone causes various complications that affect 
the patient’s life quality, and these can last for several years post cancer survival (Mundy, 
1997, Coleman, 2001). Bone complications include discrete osteolysis, diffuse osteopenia, 
osteoblastic lesions, or a mixture of all of the above (Mundy, 1997), meaning that patients 
suffer from bone pain, fractures, hypercalcaemia and spinal cord compression (Coleman, 
2001). 
1.1.4.1 Metastasis 
As detailed above, metastasis remains a major problem in the management and treatment of 
all cancers, including breast cancer (Al-Mehdi et al., 2000). This complex process involves 
individual cells detaching from the primary tumour, migrating through the lymphatic or blood 
systems, and colonizing distant sites (Friedl and Wolf, 2003, Leber and Efferth, 2009). Very 
few tumour cells that are released into the circulation successfully grow to form metastases 
(Luzzi et al., 1998, Mehlen and Puisieux, 2006) as fortunately, the metastatic process is 
inefficient (Weiss, 1990).  
Metastasis involves five steps, which are together named the metastatic cascade (Figure 1.1) 
(Leber and Efferth, 2009). The first stage is invasion and migration, initiating the metastatic 
process (Steeg, 2006, Leber and Efferth, 2009). In this step, single cells disconnect from the 
primary tumour and invade neighbouring healthy tissue (Leber and Efferth, 2009). Various 
proteolytic enzymes are produced at this stage to help in degrading the extracellular matrix 
(ECM), aiding migration (Leber and Efferth, 2009, Steeg, 2006). Second, intravasation is the 
process by which cancer cells enter the blood circulation and lymphatic vessels. Briefly, 
neoplastic cells attach to endothelial cells with the assistance of adhesion molecules, and then 
secrete proteolytic enzymes to help them penetrate the blood vessels (Leber and Efferth, 
2009). The third step is circulation, whereby these ‘stray’ cells travel through the blood 
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stream. To survive, cells must resist the high concentrations of oxygen and cytotoxic 
lymphocytes in the blood, an effective host defence mechanism to reduce the efficiency of 
the metastatic process. While this is highly effective, it has been suggested that it may 
actually select for resistant and/or aggressive tumour cells, making the treatment of secondary 
tumours more difficult (Leber and Efferth, 2009). The fourth step in the metastatic cascade is 
extravasation. Cells that travel around the blood or lymphatic system are often arrested within 
the capillaries of an organ. This provides a sufficient stationary period to allow penetration of 
the tissue through the use of proteolytic enzymes (Leber and Efferth, 2009). The fifth and last 
stage is colonization, proliferation and angiogenesis. Here, the cancer cells settle in their new 
environment, and begin to proliferate, forming a secondary tumour. For successful tumour 
growth, these colonising cells must also induce neoangiogenesis, ensuring that they having 
enough vascularization to supply the oxygen and nutrients required for further growth (Leber 
and Efferth, 2009).  
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Figure 1-1 Metastatic cascade steps. Firstly, tumour cells separate from the primary tumour 
and become less adherent. Secondly neoplastic cells invade and migrate to the surrounding 
tissue by the aid of proteolytic ezymes. After that the cancer cells entre the blood and 
lymphatic vessels via intravasation and survive in the blood stream after resisting the toxic 
conditions. Cancer cells exist the blood stream by extravasation and settle in the new distant 
site and form a secondary tumour or metastasis. Adapted from (Leber and Efferth, 2009). 
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 Introduction to matrix metalloproteinases 
Matrix metalloproteinases (MMPs) are a family of zinc dependant endopeptidases that are 
essential for degrading proteins of extracellular matrix (ECM) (Stetler-Stevenson et al., 1996, 
Bartsch et al., 2003a, Woessner, 1991, Shiryaev et al., 2013, Visse and Nagase, 2003, Itoh 
and Seiki, 2006). MMPs are a subfamily of the metzincin superfamily, and also known as 
‘matrixins’ (Seiki, 2002). The first endopeptidase was identified in a tadpole tail undergoing 
metamorphosis in 1962 by Gross and Lapiere as a collagen-degrading enzyme (Nagai et al., 
1966). This proteinase family includes the ADAMTS (a disintegrin and metalloproteinase 
with thrombospondin motifs) and the matrix metalloproteinases (Porter et al., 2005, Murphy 
and Nagase, 2008).  
The extracellular matrix consists of a complicated network of macromolecules that includes 
collagens, glycoproteins, fibronectin, laminin, proteoglycan, elastin and basement membrane 
(Aumailley and Gayraud, 1998, Woessner, 1991, Lin and Bissell, 1993), and MMPs are 
capable of breaking down all of these structural components (Woessner, 1991, Vaday and 
Lider, 2000). It is important to note that ECM remodelling is an important part of normal 
physiology; many cell types constantly produce MMPs, which are responsible for processes 
such as embryonic development, bone growth, cell proliferation, differentiation, apoptosis 
and wound healing (Velasco et al., 1999, Scherer et al., 2008). However, ECM remodelling 
beyond that required for normal physiology can lead to pathologies, such as the cellular 
invasion and migration associated with cancer (Folgueras et al., 2004, Egeblad and Werb, 
2002, Deryugina and Quigley, 2006), inflammation (Vaday and Lider, 2000, Velasco et al., 
1999, Mohammed et al., 2003), atherosclerosis (Newby, 2005, Dollery and Libby, 2006), 
multiple sclerosis (Yong et al., 2001, Rosenberg, 2005) and arthritis (Burrage et al., 2006). 
Extracellular matrix turnover and degradation is not the only function for the MMPs. Several 
studies have reported that besides degrading the matrix, MMPs also cleave non-matrix 
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substrates such as cytokines, chemokines, receptors, antimicrobial peptides (Parks et al., 
2004, Lohi et al., 2001, Seiki, 2002). Moreover, they also act on many growth factors, ligands 
and cell adhesion molecules in the extracellular milieu (Seiki, 2002). 
1.2.1 MMP family 
There are 23 members of the MMP family in humans (Kessenbrock et al., 2010, Brinckerhoff 
and Matrisian, 2002, Sterchi, 2008). MMPs are characterized according to their substrate 
specificity and general structure (Kessenbrock et al., 2010, Brinckerhoff and Matrisian, 
2002), and are divided into five broad groups: interstitial collagenases (MMP-1, MMP-8 and 
MMP-13), stromelysins (MMP-3, MMP-10 and MMP-11), gelatinases (MMP-2 and MMP-
9), matrilysins (MMP-7 and MMP-26) and membrane type MMP (MT-MMP) (MMP-14 
(MT1-MMP), MMP-15, MMP-16, MMP-17, MMP-24 and MMP-25) (Kang et al., 2014, 
Murphy and Nagase, 2008, Stetler-Stevenson et al., 1996).  
At present, Stromelysin-3 (MMP-11) and MMP-23 have no known extracellular matrix 
substrates (Lohi et al., 2001, Velasco et al., 1999), but are none-the-less included in the MMP 
family based upon structural similarity. Table 1.2 describes the human MMP family, plus 
common and alternate names for individual enzymes. 
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 Table 1-2 MMP family (Evrosimovska et al., 2011) 
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There are two major sub-types within the MMPs; those secreted in to the surrounding ECM, 
such as MMP-2 and -9; and those anchored to the cell membrane, such as MMP-14 (Spinale, 
2002, Huntley, 2012). The secreted MMPs comprise most of the known MMPs that are 
released in proenzyme state and need to be cleaved for activity (Lohi et al., 2001, Vaday and 
Lider, 2000, Spinale, 2002).  
Many cell types secrete MMP2 constitutively like fibroblasts (Arkell and Jackson, 2003, 
Kobayashi et al., 2003), whereas MMP-9 is inducible, so secreted in response to cytokines 
and growth factors (Arkell and Jackson, 2003). Secretion of MMPs by leukocytes has been 
greatly studied such as T cells (Leppert et al., 1995), neutrophils (Pugin et al., 1999), 
monocytes (Kouwenhoven et al., 2002), and B cells (Di Girolamo et al., 1998). Moreover, 
macrophages secrete wide collection of MMPs, and are considered as a main source of 
MMPs in inflammatory diseases (Elkington et al., 2009, Pugin et al., 1999). MMP secretion 
is modulated by various signalling pathways such as exocytosis (Schnaeker et al., 2004) and 
lysosomal trafficking (Glunde et al., 2003, Bramwell et al., 2015). Researchers identified two 
different populations of vesicles that contained MMP-2 and MMP-9 respectively in 
melanoma cells by immunolabeling with specific antibodies (Schnaeker et al., 2004). 
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Of particular interest to this are MMP-2 and MMP-9, which form the gelatinase subfamily 
(gelatinase A (72 kDa type IV collagenase) and gelatinase B (92 kDa type V collagenase) 
respectively). They are so called due to their preferable substrate, which is denatured collagen 
(Xia et al., 1996).  
As MMPs have been implicated in cancer metastasis (Westermarck and Kahari, 1999), and 
hence a great interest has grown in developing novel methods to inhibit MMP activity. 
Therefore, it is crucial to understand the structure and function of these significant metastatic 
players in order to identify new therapeutic discoveries for cancer (Woodhouse et al., 1997, 
Sterchi, 2008).  
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1.2.2 Structure of MMP 
All MMP family members have conserved structural and functional features (Das et al., 
2003). These include a catalytic domain that possesses the zinc binding site; an N-terminal 
pro-peptide domain; and a hemopexin-like C-terminal domain that is linked to the catalytic 
domain by a hinge region (Westermarck and Kahari, 1999, Massova et al., 1998). The overall 
structure and conserved subunits are described in Figure 1.2. 
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Figure 1-2 Structure of MMP. A) Crystallographic image of basic MMP structure showing 
propeptide region, catalytic domain and haemopexin -like domain. The orange sphere in the 
catalytic domain represents catalytic zinc whereas the blue spheres in the catalytic and in the 
haemopexin like domains represent calcium ions. Green chain represents propeptide region. 
Hinge region that links the two main domains catalytic and haemopexin-like is represented in 
white. B) Illustrative figures of the MMPs. The catalytic domain is represented in pink and in 
case of MMP-2 and MMP-9, this domain has gelatin binding domain unlike all other MMPs 
(Massova et al., 1998). 
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The main function of the pro-peptide region is to preserve the latency of the MMPs until they 
needed to be activated (Das et al., 2003). The pro-peptide domain is comprised of 80–90 
amino acids holding a ‘’cysteine switch’’ motif, a conserved unique PRCG(V/N)PD sequence 
(Nagase and Woessner, 1999). The thiol group in the cysteine residue interacts with the zinc 
atom in the catalytic domain making the MMP inactive (Massova et al., 1998, Becker et al., 
1995).  
The catalytic domain is approximately 170 amino acids in length (Evrosimovska et al., 2011). 
This domain contains a conserved zinc-binding motif, HEXXHXXGXX (H/D), and a 
methionine residue at the centre of a conserved loop referred to as the Met-turn (Gomis-Ruth, 
2009, Cerda-Costa and Gomis-Ruth, 2014). Activity of the MMP is dependent upon chelated 
ions, namely of two Zinc ions and at least one calcium ion, which are coordinated to various 
residues within the catalytic domain (Massova et al., 1998). One of the two zinc atoms is 
located in the active site of the enzyme, where it functions in the proteolytic activity of 
MMPs (Bode et al., 1994). The other zinc atom (also called the structural zinc atom) and the 
calcium atom are present in the catalytic domain approximately 12 Å away from the catalytic 
zinc (Massova et al., 1998). Not a lot is known about the function role of the structural zinc 
or the calcium atom, but their highly conserved presence in the majority MMPs suggests an 
important, as yet undiscovered, function (Bode et al., 1994).  
The final major domain within MMPs is the haemopexin-like domain, which consists of 
approximately 210 amino acids (Evrosimovska et al., 2011). The sequence of haemopexin-
like domain is similar to the plasma protein haemopexin (Massova et al., 1998). It is 
responsible for binding of either substrate molecules or the tissue inhibitors of 
metalloproteinases (TIMPs), which are endogenous inhibitors of MMPs (Borden and Heller, 
1997, Massova et al., 1998). Even though only the catalytic domain has the proteolytic 
activity, this haemopexin domain is a prerequisite for MMP functionality, allowing these 
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collagenases to break down the triple helical interstitial collagens (Nagase and Woessner, 
1999). In addition, this domain is required for pro-MMP-2 activation by MT1- MMP (Nagase 
and Woessner, 1999). While the haemopexin-like domain is considered an obligate 
characteristic for all MMPs, it is worth noting that two MMP family members are exceptions 
to this rule: MMP-23 has cysteine-rich, proline- rich and IL-1 receptor-like regions instead of 
the haemopexin domain (Nagase and Woessner, 1999); the smallest MMP, matrilysin (MMP-
7), lacks any form of haemopexin-like domain (Westermarck and Kahari, 1999). 
As shown in Figure 1.2, a hinge region exists between the haemopixin-like domain and the 
catalytic domain. The classic length of this hinge region is 16 amino acid residues, and it is 
rich in proline residues (Evrosimovska et al., 2011). Although the reason for this proline rich 
nature is not clear, it is probably necessary to add the correct level of twist in the protein 
secondary structure, creating the hinge (Nagase and Woessner, 1999). 
In contrast to the conservation of these three major domains among all MMP family 
members, there are a number of subsidiary motifs that are only found in selected MMPS 
(Figure 1.2). For example, the gelatinases MMP-2 and MMP-9 contain three repeats of a 
fibronectin type-II like motif within the catalytic domain, which has been reported to be 
implicated in the binding of gelatin within the active site (Murphy et al., 1994). This domain 
is therefore commonly referred to as the gelatin binding domain, or fibronectin type-II like 
domain. Its presence is specific for gelatinases (Massova et al., 1998). Moreover, MT-MMPs 
except MT4-MMP have a trans-membrane domain that is comprised of hydrophobic acids in 
the C-terminal end of the hemopexin domain. It is approximately 25 amino acids in length 
and acts to anchor these MMP into the plasma membrane. In addition, MT-MMPs possess a 
recognition motif (RXKR) for furin-like convertases at the end of the pro-peptide domain, 
increasing its substrate repertoire (Puente et al., 1996, Sato et al., 1996). Stromelysin 3 
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(MMP-11) is similar to MT-MMPs, being activated intracellularly by furin due to its furin 
recognition motif (Nagase and Woessner, 1999, Massova et al., 1998). 
In spite of the diversity that MMPs show in their structural domains and substrate specificity, 
the MMP have common characteristics. First, they are all thought to be zinc dependant. 
Secondly, the inhibition of MMP is by tissue inhibitors of metalloproteinase, the natural 
inhibitors, which form inactive 1:1 complexes with these enzymes. Lastly, the MMPs are 
synthesized in inactive form that requires activation to enable their function (Van Wart and 
Birkedal-Hansen, 1990). 
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1.2.3 Regulation of MMP activity  
Initially, MMPs are synthesized as an inactive form (proMMP), with cleavage required for 
proteolytic activity (Sternlicht and Werb, 2001). Under normal physiological conditions, 
MMP activity is stringently regulated at several levels, as deregulation is associated with a 
number of diseases, including cancer (Section 1.2.3.1) (Nagase et al., 2006). These levels 
include gene transcription, proenzyme activation, interaction with specific ECM components 
and inhibition by endogenous inhibitors (Visse and Nagase, 2003, Sternlicht and Werb, 
2001), and are depicted in Figure 1.3. 
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Figure 1-3 Regulation of MMP function. Activity of MMP is tightly regulated at several 
points. These levels include RNA transcription, protein translation, secretion, location, 
activation of inactive form (zymogen), endogenous inhibitors of MMP expression (tissue 
inhibitors of metalloproteinases (TIMPs) and α2-macroglobulin), and degradation of the 
MMPs. MMP activity also depends on availability of substrate and ease of access (Page-
McCaw et al., 2007). 
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Several molecules contribute to the latent MMP activation; this can be either intracellular 
through the action of furin (Kessenbrock et al., 2010, Van Wart and Birkedal-Hansen, 1990) 
or extracellular through (a) serine proteases such as plasmin, which activates proMMP3 by 
cleaving peptide bonds within MMP prodomains, or (b) through the action of already 
activated MMP species, for example MT1-MMP activating proMMP2 (Spinale, 2002, 
Kessenbrock et al., 2010, Van Wart and Birkedal-Hansen, 1990, Sternlicht and Werb, 2001, 
Scherer et al., 2008).  
1.2.3.1 Proenzyme activation 
ProMMP activation can be accomplished through the cleavage of the propeptide domain 
(Spinale, 2002). In the proMMP state, activity is repressed due to the interaction of a cysteine 
residue of the pro-domain with the zinc ion of the catalytic site. Disruption of this interaction 
leads to that MMP become proteolytically active (Kessenbrock et al., 2010, Van Wart and 
Birkedal-Hansen, 1990). This mechanism is called a cysteine switch and is mediated by 
proteolytic deletion of the pro-domain or chemical alteration of the cysteine residue 
(Kessenbrock et al., 2010, Van Wart and Birkedal-Hansen, 1990).  
The mechanism of latent MMP-2 (gelatinase A) activation has been broadly studied as MMP-
2 is an exception compared to other secreted proMMPs (Strongin et al., 1995). ProMMP2 
activation is thought to occur on the cell surface by the major physiological activators of the 
proMMP-2, which are members of the MT-MMP family (Brew et al., 2000, Hernandez-
Barrantes et al., 2002, Strongin et al., 1995, Egeblad and Werb, 2002). MT1- MMP (MMP-
14) was the first MMP to be discovered to activate proMMP-2 (Bernardo and Fridman, 2003, 
Ellerbroek and Stack, 1999, Shen et al., 2010). This process was shown to not be a simple 
interaction between proMMP-2 and MT1-MMP, but rather to require the action of the 
endogenous MMP inhibitor TIMP-2 as well (Hernandez-Barrantes et al., 2002, Brew et al., 
2000, Strongin et al., 1995, Shen et al., 2010).  
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As depicted in Figure 1.4, on the cell surface, a complex between TIMP2, MT1-MMP and 
proMMP2 are formed. The N-terminal inhibitory domain of TIMP-2 binds to MT1-MMP, 
while its C-terminal domain binds to the haemopexin-like domain of proMMP-2 (Strongin et 
al., 1995, Bernardo and Fridman, 2003, Ellerbroek and Stack, 1999, Shen et al., 2010). This 
ternary complex allows MT1-MMP to cleave the proMMP-2 into the active form (Egeblad 
and Werb, 2002), although a second, active, MT1-MMP is required to achieve full activation 
(Egeblad and Werb, 2002, Bernardo and Fridman, 2003, Ellerbroek and Stack, 1999, Shen et 
al., 2010). Although this activation process usually requires TIMP2 as the bridging factor, 
TIMP-4, a close homologue of TIMP-2, can also activate proMMP-2 (Hernandez-Barrantes 
et al., 2001). Moreover, proMMP-2 can be cleaved without the need to form the TIMP-2 
ternary complex if active MMP15 is present, as this alone is sufficient to form active MMP2 
(Egeblad and Werb, 2002).  
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Figure 1-4  A model represents activation of pro-MMP-2 mediated by MT1-MMP on 
cell surface. A) MT1-MMP active site binds to TIMP-2 amino-terminal which forms MT1-
MMP/TIMP-2 complex which serves as a receptor for pro-MMP-2. B) Haemopexin domain 
of pro-MMP-2 binds to TIMP-2 carboxyl terminal, thus forming a ternary complex on the 
cell surface. C) Another nearby active MT1-MMP cleaves the pro-peptide of ternary 
complex. It is claimed that the MMP-2 undertakes further cleavage before the release from 
the ternary complex by unknown mechanism. Adapted from (Ellerbroek and Stack, 1999).  
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1.2.4 Endogenous MMP inhibitors 
There are two major endogenous inhibitors of MMP activity: α2-Macroglobulin and the tissue 
inhibitors of metalloproteinases (TIMPs) (Hashimoto et al., 2011, Kang et al., 2014).  
α2-Macroglobulin (α2M) is a protein that exists abundantly in plasma. When it binds to any 
MMP, the resultant α2-macroglobulin–MMP complex binds to low-density lipoprotein 
receptor-related protein-1 (LRP-1), which is a scavenger receptor emptied through 
endocytosis (Emonard et al., 2005, Etique et al., 2013, Egeblad and Werb, 2002). LRP-1 
belongs to the low-density lipoprotein (LDL) receptor family and functions to clear MMPs 
whether complexed with inhibitors or not (Emonard et al., 2005, Etique et al., 2013).   
Originally, TIMPs were found as collagenase inhibitors in serum and in the conditioned 
medium from fibroblast cultures (Vater et al., 1979, Welgus et al., 1979). The balance 
between TIMPs and MMPs is a crucial element in regulation of the total MMPs proteolytic 
activity (Shiryaev et al., 2013). TIMPs form highly affinity 1:1 stoichiometric complexes 
with MMPs, through a non-covalent interaction (Duffy et al., 1995, Visse and Nagase, 2003, 
Avolio et al., 2005). In addition, to the ability of TIMP proteins to bind to active MMP family 
members, they also bind to the proMMPs, effectively preventing activation (Avolio et al., 
2005).  
There are four TIMPs in human, named TIMP-1, TIMP-2, TIMP-3, and TIMP-4, which 
range in size from 22 to 29KDa. TIMP-1 and TIMP-3 are subject to post-translational 
modification, in particular glycosylation, while TIMP-2 and TIMP-4 are not glycoproteins 
(Baker et al., 2002). As expected, glycosylation of TIMPs is associated with membrane 
interaction, but TIMP family members may also be soluble; specifically TIMP-1 and TIMP-2 
may exist in soluble and insoluble forms, while TIMP-3 is considered insoluble only 
(Ellerbroek and Stack, 1999). In general, TIMPs have a broad MMP target profile; for 
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example, TIMP-2 and TIMP-3 can inhibit all MMPs to variable degrees, related to their 
affinity to each MMP. However, TIMP-1 shows some restriction in target MMPs, and is able 
to poorly inhibit MT1-MMP (MMP-14) (Ellerbroek and Stack, 1999). Despite this relatively 
promiscuous interaction portfolio, TIMP-1 and TIMP-2 have a preference towards MMP-9 
and MMP-2, respectively (Stetler-Stevenson et al., 1989, Wilhelm et al., 1989, Avolio et al., 
2005). In contrast to the binding of TIMP2 to proMMP2 during its activation (section 
1.2.3.1), TIMP2 binding to MMP2 for inactivation occurs via the carboxyl-terminal domains 
of both the TIMPs and the MMPs (Stetler-Stevenson et al., 1996, Duffy et al., 2000). 
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1.2.5 MMP in cancer 
Cancer hallmarks include migration, invasion, metastasis and angiogenesis, and matrix 
metalloproteinases are implicated in all of these processes (Gialeli et al., 2011). The ability of 
MMPs to initiate extracellular matrix proteolysis and tissue remodelling is an essential 
requirement for tissue development. However, tissue remodelling is also essential for cancer 
cell invasion and metastasis (Bendrik et al., 2008), and abnormal expression of MMPs has 
been associated with malignancy (Rundhaug, 2003). Moreover, this level of expression 
appears to be positively associated with aggressive tumour phenotypes, with the activity of 
MMPs having been shown to be elevated in invasive or metastatic neoplasms compared to 
non-invasive tumours (Yang et al., 2003). This over-expression appears to be a consistent 
feature of aggressive tumours from many tissues, having been detected in tumours that 
include brain, colon, lung, bladder, melanoma, cervical, prostate and breast (Sprague et al., 
2006, Rasmussen and McCann, 1997). Poor prognosis has been well documented with 
metastatic cancers expressing high levels of MMPs, in particular breast carcinoma (Sprague 
et al., 2006). 
While the association between MMP activity and tumour aggression is strongly supported by 
clinical data, the molecular aetiology of this phenomenon is not clear. For example, it is not 
completely clear whether MMP activity/secretion is directly from cancerous cells or from the 
surrounding healthy cells (Chin et al., 2005).  
 
Gelatinase-A (MMP-2) and Gelatinase-B (MMP-9) are the amongst MMPs that have been 
associated with both breast cancer development and progression (Singer et al., 2002). During 
the early stages of breast cancer, MMP-2 is believed to be produced by stromal cells where it 
has an important role in tumour angiogenesis and metastasis (Shen et al., 2010, Sato et al., 
1994). In comparison,  MMP-9 is thought to be linked with lymph node metastasis in breast 
carcinoma (Singer et al., 2002). 
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As levels of MMP-2 and MMP-9 are elevated in plasma or tumour tissue in a wide range of 
cancers, these MMPs have been suggested as general prognostic indicators, positively 
associated with higher incidence of metastases (Deryugina and Quigley, 2006, Vihinen et al., 
2005). 
Therapeutic strategies based on MMP activity inhibition have been under serious 
investigation, with MMP inhibitors (MMPIs) based on hydroxamic acid derivatives or other 
synthetic inhibitors in clinical trials (Vihinen et al., 2005, Hashimoto et al., 2011). However, 
to date, results of the clinical trials in metastatic cancer are disappointing because of the toxic 
side effects limiting drug exposure (Hashimoto et al., 2011, Vihinen et al., 2005).  
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 Nuclear receptors  
Nuclear receptors (NR) are a superfamily of ligand-activated transcription factors. They 
regulate many key biological functions, such as regulation of cell growth, differentiation, 
reproduction, homeostasis, embryonic development, cell death and metabolism (Chawla et 
al., 2001, Wang et al., 2004, Giguère, 1999, Gronemeyer and Laudet, 1995, Mangelsdorf et 
al., 1995, Mangelsdorf and Evans, 1995, Beato et al., 1995). Not surprisingly, disturbance in 
nuclear receptor pathways has been shown to cause abnormality in cellular homeostasis, and 
is associated with disorders such as cancers, obesity, and diabetes (Wang et al., 2004). As 
such, members of this superfamily have become very important targets in medical research 
and drug discovery (Wang et al., 2008, Enmark and Gustafsson, 1996). 
There are 48 nuclear receptor genes in humans (1999, Chawla et al., 2001, Wang et al., 
2008). These 48 receptors share a common overall structure and mode of action (Figure 1.5). 
Following nuclear receptor binding to a ligand, conformational change occurs, leading to 
DNA binding as homodimers or heterodimers (Leid et al., 1992). In addition, this binding 
increases the affinity for coactivator molecules for instance steroid receptor coactivator 1 
(SRC-1), a critical step in formation an active transcription complex (Makishima et al., 
1999). 
In structure, nuclear receptors consist of five domains called A/B, C, D, E and F. The two 
defining domains for each nuclear receptor family member are C and E, which represent the 
DNA binding domain and ligand binding domain, respectively (Gronemeyer and Laudet, 
1995). The DNA binding domain is the site of interaction between the nuclear receptor and 
its cognate DNA response element, often referred to as the hormone response element 
(Mangelsdorf et al., 1995). This domain contains two zinc fingers that intercalate with the 
DNA through non-covenant interactions, and orientate the nuclear receptor to aid in 
transcriptional activation (Mangelsdorf et al., 1995). In general, nuclear receptors recognise a 
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variant of the DNA binding motif AGGTCA, binding as either monomers to a single repeat, 
or as (homo/hetero) dimers to a repeat motif. The relationship of the two binding sites (i.e. 
direct, inverted or everted repeat) and the gap between these repeats (between 1 and 8 
nucleotides) is an important determinant of binding specificity (Xiao et al., 2013). Given this 
shared functionality, it is not surprising that many nuclear receptors share a high (>90%) 
sequence similarity in this region (Mangelsdorf et al., 1995). The only exceptions to this are 
DAX1 and SHP, neither of which contain a DNA binding domain (DBD). Indeed, this is 
essential for their mode of action, whereby they can squelch the activity of other nuclear 
receptors by forming non-functional dimers that cannot bind to DNA (Swain et al., 1998, 
Goodwin et al., 2000). 
In contrast to the high similarity in DNA binding domain sequence, the ligand binding 
domain (LBD) of nuclear receptors shows considerably more variability between superfamily 
members, which is necessary for recognition of the wide range of ligands (Mangelsdorf et al., 
1995). The LBD has the essential role of ligand recognition that guarantees both specificity 
and selectivity of the subsequent biological response (Mangelsdorf et al., 1995). Within this 
region of the nuclear receptor also exists the AF-2 region, which plays a role in the ligand-
dependent protein-protein interactions key to co-activator recruitment and full transcriptional 
activity (Wang et al., 2004, Mangelsdorf et al., 1995). 
In addition to these two major domains within a nuclear receptor (C and E), there are three 
more domains that impact upon functionality: firstly, the D domain is a flexible hinge region 
between the DBD and LBD, allowing correct orientation of the protein structure. In addition, 
the hinge region is important in nuclear translocation, and contains a nuclear localization 
signal (Steinmetz et al., 2001, Laudet, 1997): secondly, the A/B region at the N-terminal side 
of the protein is involved in transcription regulation in both ligand-activated and ligand-
absent protein forms (Steinmetz et al., 2001, Beato et al., 1995, Gronemeyer, 1993). This 
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region is often referred to as the AF-1 region and is highly variable between nuclear 
receptors: thirdly, at the C-terminal end of the protein is the F domain, which is a highly 
variable region of limited functionality.  
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Figure 1-5 A typical model of a nuclear receptor. In the upper image, the NR has DNA 
binding domain (DBD), Ligand binding domain (LBD), N-terminal domain (AF1) which is 
variable, C-terminal domain (AF2) which is variable, Hinge region is between the two main 
domains DBB & LBD. The lower image illustrates mechanism of nuclear receptor action 
(Mangelsdorf and Evans, 1995).  
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The main function of nuclear receptors is gene expression regulation either positively or 
negatively at the transcription level. The transcriptional control by nuclear receptors includes 
activation, repression and transrepression (Glass and Saijo, 2010). Transcriptional activation 
that depends on presence of a ligand, alters the ligand binding domain and thus decreases the 
receptors affinity for corepressors and increases the receptor affinity for coactivators (Glass 
and Saijo, 2010). Coactivators and corepressors are called coregulators and they are essential 
for effective transcriptional regulation (O'Malley, 2006, Rosenfeld et al., 2006). Several 
coactivators were recognized such as members of the steroid receptor coactivator (SRC) 
subfamily (Glass and Saijo, 2010). Coactivators affect receptor transcription by a range of 
mechanisms that involve acetylation, methylation, phosphorylation and chromatin 
remodelling (Tetel, 2009). Besides transcription activation, nuclear receptors also inhibit 
expression of genes by repression which is direct binding to a negative response element or 
by transrepression which is antagonising other transcription factors by interaction with their 
regulators (Ordonez-Moran and Munoz, 2009). Transcriptional regulation is tightly 
controlled from gene repression to gene activation. Retinoic acid and thyroid hormone 
receptors are a decent example that represents such regulation. Retinoic acid and thyroid 
hormone receptors use NCoR/SMRT corepressor complexes in absence of ligand which leads 
to transcriptional repression. Upon ligand binding, the corepressor complexes are exchanged 
for coactivator complexes which switch on the transcription (Chen and Evans, 1995, Horlein 
et al., 1995, Heinzel et al., 1997, Alarid et al., 1999, Privalsky, 2004). 
Whereas the classical function of nuclear receptors is to regulate transcription of many target 
genes through ligand binding to regulatory regions within their DNA (genomic effects), many 
non-genomic actions of nuclear receptors were revealed (Losel et al., 2003). Recent studies 
on steroid and vitamin D receptors suggested that there is a distinctive mode of action of 
nuclear receptors that both genomic and non-genomic effects are incorporated wherein the 
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non-genomic actions are obligatory for the effects at the genome level (Ordonez-Moran and 
Munoz, 2009). The steroid receptors non-genomic effects are mediated through membrane 
receptors which are different from their classic action (Wang et al., 2014). A study by Moraes 
et al., showed the functional cross-talk between RXR and the G-protein Gq in platelets, 
which does not have a nucleus, that represents RXR nongenomic affect (Moraes et al., 2007).  
Nuclear receptors are divided into groups according to DNA binding, ligand binding and 
dimerization feature (Figure 1.6) (Mangelsdorf et al., 1995). These groups are endocrine 
receptors, adopted orphan receptors, and orphan receptors (Chawla et al., 2001). The orphan 
receptors are so-called as they have no distinct ligands (Enmark and Gustafsson, 1996, 
Laudet, 1997). The orphan receptors have no known endogenous ligand of high affinity, such 
as hepatic nuclear factor 4. The endocrine receptors group comprises those nuclear receptors 
whose main endogenous ligands are steroid hormones, such as the glucocorticoid and 
oestrogen receptors. Finally, the adopted orphan receptors are those nuclear receptors 
originally classified as orphan, but for whom endogenous ligands have been identified, such 
as is the case with the pregnane X-receptor (Chawla et al., 2001).  
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Figure 1-6 Nuclear receptor superfamily. Nuclear receptor superfamily is divided into 
three or four groups depending on the ligand type. Nuclear receptors have common functions 
and structures (Chawla et al., 2001).  
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1.3.1 Farnesoid X receptor  
The Farnesoid X Receptor (FXR; NR1H4) is a member of nuclear receptor superfamily of 
ligand-dependant transcription factors (Forman et al., 1995, Mangelsdorf and Evans, 1995). 
Originally, FXR was demonstrated to be activated by high concentrations of cholesterol 
synthesis intermediate, the isoprenoid farnesol, from which the nuclear receptor derived its 
name (Forman et al., 1995). However, further investigations demonstrated that FXR 
functions as a bile acids sensor, for which the receptor has a higher affinity (Makishima et al., 
1999, Parks et al., 1999). The affinities of bile acids towards FXR vary, with primary bile 
acids generally having higher affinities. For example, the primary bile acid chenodeoxycholic 
acid (CDCA) has the highest affinity of any natural bile acid, with a Kd in the region of 
14µM (Makishima et al., 1999, Parks et al., 1999, Wang et al., 1999, Han et al., 2010). In 
contrast, the secondary bile acid lithocholic acid, which is formed by cleavage of CDCA by 
gut bacteria, is an antagonist of FXR, with a Kd in the region of 8µM (Yu et al., 2002).  
There are two FXR genes in human, designated FXRα and FXRβ (Otte et al., 2003, Forman 
et al., 1995). The FXRα gene product functions in all species, whereas FXRβ produces a 
functional protein product in mice, rats, rabbits, and dogs but in human is a pseudogene (Otte 
et al., 2003). In addition to these two genes, there are a number of common splice variants 
within FXRα, resulting in four isoforms (FXRα1–4) of murine (Zhang et al., 2003) and 
human (Huber et al., 2002) FXRα. 
The four FXR isoforms are expressed in a tissue-specific manner (Huber et al., 2002, Zhang 
et al., 2003). FXR is highly expressed in liver and intestine, kidneys and adrenal gland 
(Forman et al., 1995). FXR is expressed at low levels in heart, vascular tissue, thymus, ovary, 
spleen, and testes (Bishop-Bailey et al., 2004, Otte et al., 2003). However, the physiological 
roles of these different FXR isoforms is not known (Chen et al., 2013, Vaquero et al., 2013), 
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and indeed the role of FXR in nonenterohepatic tissues is still a matter of some debate 
(Swales et al., 2006, Lee et al., 2011).  
When FXR is activated by its natural or synthetic ligands, it binds to FXR response elements 
(FXREs) on the DNA either as a monomer or heterodimer with Retinoid x receptor (RXR) 
and thus switch on gene transcription of target genes (Stojancevic et al., 2012, Jiang et al., 
2013). FXREs consist of two inverted repeats (IRs) of AGGTCA sequence, which is 
separated by one nucleotide IR-1 (Laffitte et al., 2000, Stojancevic et al., 2012, Jiang et al., 
2013, Modica and Moschetta, 2006). Following FXR activation by a ligand, it undergoes 
conformational changes, translocated to the nucleus, and employ coactivators such as steroid 
receptor coactivator (SRC)-1(Claudel et al., 2005, Stojancevic et al., 2012). However, when 
ligand is not bound, a corepressor is linked with the FXR/RXR heterodimer which in turn 
blocks transcription of target genes by FXR (Stojancevic et al., 2012).  
Once activated, the primary target genes for FXR are those that control synthesis, conjugation 
and transport of bile acids (Claudel et al., 2004). However, FXR has wider roles other than 
bile acid homeostasis: it regulates lipid and cholesterol homeostasis (Niesor et al., 2001, 
Zhang et al., 2006, Cariou et al., 2006, Bilz et al., 2006, Lambert et al., 2003),  carbohydrate 
and glucose homeostasis (Stayrook et al., 2005, Cariou et al., 2006, Ma et al., 2006), and has 
roles in amino acid transport (Downes et al., 2003), liver regeneration (Huang et al., 2006), 
and gastrointestinal defence (Inagaki et al., 2006). Recent studies have shown that FXR may 
represent a valuable therapeutic target for treating dyslipidaemia and cholestasis (Claudel et 
al., 2004). Experimental evidence has shown the critical role in bile acid and lipid 
homeostasis of FXR, using targeted disrupted in mice (Kim et al., 2007a, Sinal et al., 2000). 
The resulting phenotype, juvenile –onset cholestasis, demonstrates that FXR is critical to 
sensing, and maintaining the levels of bile acids within normal physiological bounds.   
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In the liver, the classic pathway for bile acids synthesis from cholesterol catabolism occurs 
when the liver X receptor (LXR), another nuclear receptor closely related to FXR, is 
activated by oxysterols (Goodwin et al., 2000, Peet et al., 1998). This up-regulates the 
expression of two key catabolic enzymes, cytochrome P450 7A1 (CYP7A1) and CYP8B1, 
which results in an increased breakdown of cholesterol into primary bile acids (Lee et al., 
2006a, Davis et al., 2002). CYP7A1 is also known as cholesterol 7α-hydroxylase and is the 
rate-limiting enzyme in this pathway (Jelinek et al., 1990), whereas sterol 12α-hydroxylase 
(CYP8B1) initiates the production of cholate, setting the cholate:CDCA ratio (Sinal et al., 
2000). The role of FXR as a bile sensor is to prevent over accumulation of cholate and 
CDCA, high levels of which cause cholestasis. Once activated by elevated level of these 
primary bile acids, FXR acts to repress the cholesterol catabolic pathway indirectly by 
inducing gene expression of the nuclear receptor, the small heterodimer partner (SHP). SHP 
can heterodimerize with liver receptor homolog 1 (LRH-1), leading to downregulation of 
CYP7A1, thus decreasing bile acids production (Goodwin et al., 2000, Lu et al., 2000). By 
this action, FXR protects the liver from accumulation of toxic bile acids and xenobiotics 
(Chiang, 2002). This metabolic pathway and the protective interplay of FXR, LXR and SHP 
are depicted in Figure 1.7. 
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Figure 1-7 Role of FXR in bile acids transport, biosynthesis, absorption and lipid 
homeostasis. Blue arrows indicate breakdown, transport, and interaction of receptor/ligand 
steps. Black arrows indicate targets for positive transcription while red arrows indicate 
negative transcription for FXR target genes. LXR regulates transcription of Cyp7a, but the 
effect on Cyp8b transcription is not recognized. Furthermore, indirect regulation of Cyp7a 
though FXR by induction of SHP which heterodimerises with LRH-1. Adapted from (Sinal et 
al., 2000). 
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1.3.2 Activation of FXR 
1.3.2.1 Bile acids 
Bile acids (BAs) are the end-products of cholesterol catabolism in the liver (Claudel et al., 
2005, Baptissart et al., 2013). After synthesis in the liver, bile acids are transported to the 
intestine to assist in fat-soluble vitamins and dietary fat absorption (Claudel et al., 2005). 
Seventy percent of the bile acids transported to the intestine are re-absorbed by the liver 
through the enterohepatic circulation, with the remaining 30% being excreted (Claudel et al., 
2005).  
FXR is a chief player in the bile acids metabolic biosynthesis pathway. In addition to its 
regulation of bile acids synthesis, as described in section 1.3.1, it is also involved in their 
conjugation and transport (Claudel et al., 2005, Chiang, 2002). Bile acids may be divided into 
two groups: primary bile acids are produced in the liver, while secondary bile acids are 
formed in the intestine by bacteria (Baptissart et al., 2013). CDCA and CA are primary bile 
acids whereas LCA and DCA are secondary bile acids (Willson et al., 2001).  
Outside the endogenous FXR ligands, the bile acids (Parks et al., 1999, Makishima et al., 
1999, Wang et al., 1999), a number of synthetic, selective FXR ligands have been developed. 
These include the high-affinity nonsteroidal FXR agonist GW4064 (Maloney et al., 2000), 
Fexaramine (Downes et al., 2003), AGN34 (Dussault et al., 2003), steroidal FXR agonist 6α-
ethyl-chenodeoxycholic acid (6-ECDCA) (Pellicciari et al., 2002) and WAY-362450 
(XL335) (Flatt et al., 2009). The development of these more selective and potent agonists 
brought crucial insights into the role of FXR in metabolism, and as such were more likely to 
(a) produce detectable effects, and (b) reduce the degree of off-target effects that confound 
mechanistic interpretation. For example 6-ECDCA is a synthetic, modified form of CDCA, 
and is approximately 87-fold more potent and specific than the primary bile acid it was 
derived from (Pellicciari et al., 2002). In addition, CDCA interacts with bile acid binding 
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transport proteins, and is metabolised in the intestine to produce lithocholic acid, all of which 
act to confound understanding of FXR biology due to potential feedback effects (Setchell et 
al., 1997). A selection of endogenous and synthetic FXR ligands are shown in Figure 1.8. 
 
 
 
 
 
 
 
Figure 1-8 Natural and synthetic FXR agonists. Bile acids are the natural ligands of FXR 
that are synthesized from metabolism of cholesterol by FXR. Cholesterol 7α-hydroxylase 
(CYP7A1) is the rate-limiting enzyme that breaks down the cholesterol into bile acids 
(CDCA). Sterol 12α-hydroxylase (CYP8B1) produces CA from CDCA. 6-ECDCA is the 
altered form from CDCA. The ligands in blue are the FXR synthetic ligands, whereas the 
ligands in red are the endogenous (Zhang, 2010).  
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There are additional nuclear receptors for bile acids apart from FXR such as vitamin D3, 
retinoids (RAR, RXR), and thyroid hormone receptors (Zimber and Gespach, 2008). Vitamin 
D3 receptor is specifically and effectively activated by LCA (Makishima et al., 2002). 
Moreover, other laboratories reported that pregnane X-receptor (PXR) is also activated by the 
natural LCA (Staudinger et al., 2001, Xie et al., 2001, Zimber and Gespach, 2008). PXR is 
thought to be inhibitory for bile acids synthesis and enhance CYP3A4 to clear LCA, thus 
protecting the liver against toxicity (Staudinger et al., 2001). Besides the intracellular nuclear 
receptors, bile acids are also ligands for a cell surface receptor that was identified by two 
research groups which is called G protein-coupled receptor, TGR5 (M-BAR, GPBAR1) 
(Kawamata et al., 2003, Maruyama et al., 2002). According to a study by Maruyama et al., 
they suggest that the two independent bile acids pathways; membrane-type G protein-coupled 
receptor for quick signalling and nuclear receptors for late signalling (Maruyama et al., 
2002).  
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1.3.3 Target genes of FXR 
FXR regulates transcription of various genes involved in both bile acids biosynthesis and 
transport. The main target gene of FXR is SHP, which is a direct target expressed in the liver 
(Lu et al., 2000). Upon activation by bile acids, FXR acts to prevent further bile acid 
production through inhibition of CYP7A1 and CYP8B1; this is achieved indirectly by up-
regulation of SHP, which with another nuclear receptor LRH-1, represses CYP7A1- and 
CYP8B1-dependent biosynthesis of bile acids from cholesterol (Goodwin et al., 2000, Lu et 
al., 2000, Seol et al., 1998). As previously described (section 1.3), SHP is an orphan member 
of the nuclear hormone receptor superfamily that lacks the conserved DNA binding domain, 
but contains dimerization and ligand-binding domains (Seol et al., 1996). As such it can 
prevent activity of other nuclear receptors through the process of squelching.  
In addition to its action of SHP expression, FXR controls the gene expression for many other 
proteins involved in drug metabolism. These include drug transporters, such as the bile salt 
export pump (BSEP) that is responsible for enhanced efflux of bile acids (Ananthanarayanan 
et al., 2001, Plass et al., 2002). On the other hand, FXR activation leads to downregulation of  
the transcription of sodium taurocholate cotransporting peptide (NTCP) and sodium-
dependent bile salt transporter (ASBT), which is involved in the uptake of bile acids into the 
hepatocyte in the liver (Sinal et al., 2000) (Neimark et al., 2004). In addition, FXR regulates 
transactivation of more transporters such as ileal bile acid binding protein (IBABP) and ileal 
bile acid transporters (IBAT) that are important elements in the enterohepatic circulation of 
bile acids (Hwang et al., 2002, Lee et al., 2006b, Makishima et al., 1999). Together, these 
actions tend to decrease hepatocyte bile acid levels through increased efflux and decreased 
absorption, an important part in the return to homeostasis. 
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FXR regulates the expression of a range of other drug transporters, including the human 
organic solute transporters α and β (OSTα & OSTβ), which are expressed the adrenal gland, 
kidney, and intestine (Landrier et al., 2006, Lee et al., 2006b). Multidrug resistance protein 3 
(MDR3) (Huang et al., 2003) and the multidrug resistance-associated protein 2 (MRP2, 
ABCC2) (Kast et al., 2002) are other genes that are controlled by FXR, and they are involved 
in trans-location of phospholipids and other compounds through canalicular membranes of 
hepatocytes (Huang et al., 2003, Kast et al., 2002).  
IBABP and other FXR target genes syndecan-1 (Anisfeld et al., 2003) and α-crystallin (Lee 
et al., 2005) are regulated in an isoform specific manner. FXRα2 and FXRα4 are involved in 
regulating these target genes and MYTG motif seems to be missing these isoforms (Zhang et 
al., 2003). However, SHP, BSEP and phospholipid transfer protein (PLTP) (PLTP is FXR 
target gene that is involved in high density lipoprotein metabolism (HDL)) (Urizar et al., 
2000) are regulated by all four FXR isoforms to the same degree (Zhang et al., 2003).   
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1.3.4 Involvement FXR in cancer 
Novel roles for FXR other than its role in metabolism were revealed recently in many non-
enterohepatic tissues, including its role in cell growth regulation and carcinogenesis 
(Catalano et al., 2010). In FXR-null mice, hepatocarcinogenesis occurred spontaneously, 
including hepatocholangiocellular carcinoma and hepatocellular adenoma, consistent with a 
positive action of FXR in tumour growth (Kim et al., 2007b). Other studies produced data 
consistent with these findings: Zhang et al have shown that FXR down-regulation by miR-
421 induced proliferation, migration, and invasion of hepatocellular carcinoma cells (HCC) 
(Zhang et al., 2012), while Modica et al demonstrated similar findings that FXR repressed 
intestinal carcinogenesis when it was activated by its ligands (Modica et al., 2008). In 
pancreatic cancer, FXR activation induced lymph node metastasis, leading to the proposal 
that FXR-antagonists may represent a novel class of therapeutics to retard pancreatic tumour 
development (Lee et al., 2011).  
However, the exact mechanistic role that FXR plays in growth regulation, cancer, and 
apoptosis are still unclear and controversial. For example, studies have reported both positive 
and negative associations between expression of FXR and incidence of cancer, thus providing 
no definitive relationship (De Gottardi et al., 2006, Kim et al., 2007b, Journe et al., 2008, 
Modica et al., 2008, Maran et al., 2009, De Gottardi et al., 2004, Zhang et al., 2012, Lee et 
al., 2011). On this basis, the function of FXR in cancer, in general, and its role in pro-survival 
(e.g. migration, invasion and proliferation) or anti-survival (e.g apoptosis), specifically, 
remain an area that requires further study (Lee et al., 2011). 
Recently, FXR expression was detected in breast cancer tissues and breast cancer cell lines in 
several studies (Silva et al., 2006, Swales et al., 2006, Journe et al., 2008). Further studies 
showed that FXR expression was related to proliferation of estrogen receptor-positive 
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luminal-like breast cancer in postmenopausal women, and FXR was also associated with 
tumour invasiveness and metastasis in this tissue (Journe et al., 2009).  
 As breast cancer occurrence has been linked to high-fat diets, it would be logical to presume 
that higher levels of circulating bile acids would also be present. This was indeed the case, 
with bile acids found in large amounts in the systemic circulation of postmenopausal women 
diagnosed with breast cancer (Costarelli and Sanders, 2002). Other studies showed that bile 
acids are implicated in other cancers such as esophageal and colon tumours (Zimber and 
Gespach, 2008, Debruyne et al., 2001). Swales et al demonstrated that activation of FXR by 
either CDCA or GW4064 induced apoptosis and inhibited the growth of breast cancer cell 
lines MCF-7 and MDA-MB-468 (Swales et al., 2006), while FXR activation inhibited MCF-
7 tamoxifen resistant growth (MCF-7TR) (Giordano et al., 2011). These data are consistent 
with the higher circulating levels of bile acids, and hence higher FXR activation, being a 
protective adaptation, acting to remove the tumour. However, not all studies are consistent 
with such a hypothesis: Silva et al showed that inhibition of FXR by the antagonist Z-
guggulsterone induced apoptosis in MDA-MB-231 and prevented migration of these cells 
(Silva et al., 2006). Hence, the exact role of FXR in tumour progression is unclear, with 
evidence for both tumour-prevention and tumour-survival. It is thus important to undertake 
further studies to delineate the role of FXR activation in tumour aetiology.  
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 Role of FXR in MMP regulation 
Given the evidence that FXR activation may be important for the development of a pro-
survival phenotype in tumours, it would be logical to hypothesis that FXR may interact with 
proteins involved in tumour growth, invasion and metastasis, such as the MMPs. However, 
few studies have examined the role of FXR in MMP regulation. Fiorucci et al. reported that 
in hepatic stellate cells (HSCs), the FXR-SHP regulatory cascade was involved in the 
regulation of tissue metalloproteinase inhibitor-1 (TIMP-1) and matrix metalloprotease 
(MMP) expression (Fiorucci et al., 2005). In addition, a study by Li, et al., reported that the 
FXR agonist 6ECDCA decreased both MMP-2 and -9 activities and gene expression in the 
presence or absence of IL-1β in vascular smooth muscle cells (Yoyo T.Y. Li et al., 2006). 
Both of these data are consistent with a protective effect of FXR activation, leading to a 
reduction in MMP activity and, hence, invasion potential. However, it has also been 
demonstrated that FXR activation induced cell motility in blood outgrowth endothelial cells 
(BOECs) (Das et al., 2006). FXR-mediated induction of SHP led to dissociation of the 
SP2/KLF6 complex, which is required to repress expression of MMP-9. This data would 
support a pro-survival role for FXR activation, through an increased expression of MMPs. 
Once again, the literature is conflicted and further studies are required to fully understand the 
implications of FXR expression and activation in developing tumours. 
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 Hypothesis and Objectives 
The purpose of the present study was to test the hypothesis that FXR is a novel therapeutic 
target for breast cancer progression and metastasis.  
GW4064 was identified to be a potential tool to characterize FXR function (Bass et al., 2009, 
Maloney et al., 2000), because it is selective agonist of FXR (Howarth et al., 2010). As bile 
acids activate many nuclear receptors for instance pregnane X receptor (PXR, NR1I2) and 
vitamin D receptor (VDR, NR1I1) (Xie et al., 2001, Makishima et al., 2002, Wang et al., 
2002). 
 
Objective 1: Measuring the effects of FXR ligands on cell viability. 
 Treating all breast cancer and normal breast cell lines with FXR ligands natural 
CDCA and synthetic GW4064 for 48 and 72 hours under 10% serum and serum free 
conditions and measuring the effects of FXR activation on cell viability by MTT 
assay. 
 
Objective 2: Measuring the effects of FXR ligands on protein and mRNA levels of MMP-2, 
MMP-9, TIMP-1 and TIMP-2. 
 Treating both cell lines MDA-MB-468 and MCF-7 with FXR ligands CDCA and 
GW4064 for 24 hours and preparing protein and RNA extracts and measure them by 
Western blotting, RTPCR, and also by ELISA in the conditioned media collected. 
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Objective 3: Measuring the effects of FXR ligands on MMP activity. 
 By gelatin zymography and also by a fluorescence-based assay using MMP2/MMP-9 
fluorescent substrate and conditioned media collected from cell viability experiments. 
 
Objective 4: Measuring the effects of FXR ligands on cell migration 
 Pre-treating breast cancer and normal breast cell lines with FXR agonist GW4064 for 
one hour prior to seeding in the transwells and incubating them for 72 hours and 
measuring by transwell migration assay, and also by using wound healing assay.
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2 Materials and Methods 
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 Materials 
All materials were from Sigma-Aldrich (Poole, UK) and of molecular or cell-culture grade, 
as appropriate, unless otherwise stated. 
Table 2-1 Materials and suppliers used 
Material Supplier 
Chemicals Used 
GW4064 Tocris Biosciences, Abingdon, UK 
Chenodeoxycholic Acid (CDCA) Sigma-Aldrich, Poole, UK 
Phorbol 12-myristate 13-acetate (PMA) Sigma-Aldrich, Poole, UK 
Epidermal growth factor (EGF) Sigma-Aldrich, Poole, UK 
Interleukin-1 beta (IL-1β) Sigma-Aldrich, Poole, UK 
Insulin-like growth factor 1 (IGF-1) Sigma-Aldrich, Poole, UK 
All-Trans Retinoic Acid (ATRA) Sigma-Aldrich, Poole, UK  
Gelatin Zymography & Western Blotting 
Amicon Centrifugal Filter Units (10k 
filter) 
Merck Millipore, Massachusetts, USA 
MMPs and TIMPs standards Enzo life sciences, Exeter, UK 
Spectra Multicolour Broad Range 
Protein ladder 
Fermentas, Loughborough, UK 
Protease Inhibitor Tablets Roche, Lewes, UK 
Acrylamide stock solution 40%  
Bisacrylamide stock solution 2% 
VWR,  Lutterworth, UK 
Hybond-C Extra Nitrocellulose 
Membrane 
GE Healthcare, Buckinghamshire UK 
Microporous PVDF Western Blotting 
Membrane (0.45μm) 
Roche, Lewes, UK 
Primary and secondary antibodies Santa Cruz Biotechnology, CA, USA 
β-Actin and TIMP-2 Primary antibodies Sigma-Aldrich,  Poole, UK 
Dried Skimmed Milk Marvel, Dublin, Ireland 
Pierce SuperSignal West pico 
chemiluminescent Kit  
Thermo scientific, IL, USA  
 
Developer, Fixer, Hardener Champion Photochemistry, Essex, UK 
Restore Western Blot Stripping Buffer Thermo Scientific, IL, USA 
X-Ray Film Thermo scientific, IL, USA  
Real Time PCR 
TRIzol® Reagent Invitrogen, Paisley, UK 
Dnase, Dnase stop solution, buffers Promega, Southampton, UK 
Reverse Transcription kit, Master Mix 
with low level Rox 2x 
Primer Design, Southampton, UK 
 
Primers and probes sets  Eurofins MWG Operon, Alabama, USA  
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Gelatin cleavage assay 
MMP-2/MMP-9, MMP-1/MMP-9 
Fluorogenic Substrates, Recombinant 
MMP-9 and MMP-2 
Calbiochem by Merck Millipore, 
Nottingham, UK 
 
ELISA 
MMP-2 (ab100606), MMP-9 (100610), 
TIMP-1 (ab100652), TIMP-2 
(ab100653) ELISA kits 
Abcam, Cambridge, UK 
Migration and Invasion assay 
Transwell Inserts 6.5 mm Corning Incorporated, USA 
Growth Factor Reduced Matrigel 
Matrix 
BD Biosciences, USA 
Wound healing assay 
Culture-insert in µ-Dish 35 mm, low, 
ibiTreat 
Ibidi, Martinsried, Germany 
 
 
Table 2-2 Primers and TaqMan probes used for Real Time PCR 
Gene  Primers and Probes  Sequence  
Human 
MMP2 
 
Forward primer  
Reverse primer 
Probe 
GGACACACTAAAGAAGATGCAGAAGT 
CGCATGGTCTCGATGGTATTC 
ACTGCCCCAGACAGGTGATCTTGACC 
Human 
MMP9 
 
Forward primer  
Reverse primer 
Probe 
CCCGGAGTGAGTTGAAC 
GGATTTACATGGCACTGCCA 
ATGACATCCTGCAGTGCCCTGAGGACTA 
Human 
TIMP1 
 
Forward primer  
Reverse primer 
Probe 
CTGCGGATACTTCCACAGGTC 
GCAAGAGTCCATCCTGCAGTT 
CACAACCGCAGCGAGGAGTTTCTCA 
Human 
TIMP2 
 
Forward primer  
Reverse primer 
Probe 
ATAAGCAGGCCTCCAACGC 
GAGCTGGACCAGTCGAAACC 
CTGTGGCCAACTGCAAAAAAAGCCTC 
 
 
Table 2-3 Software used 
Software Supplier 
Image J  Wayne Rasband, NIH, Maryland, USA  
7500 Real Time PCR system software  Applied Biosystem, California, USA 
Tscratch Chair of computational Science, Zurich, Switzerland  
GraphPad PRISM v6.0 GraphPad Software Inc. California, USA 
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 Methods 
2.2.1 Cell culture 
The breast tumour and normal breast cell lines MDA-MB-468 (Catalog no. HTB-132), 
MCF10A Catalog no. (ATCC-CRL-10317), respectively, were purchased from American 
Type Culture Collection (ATCC), while the breast tumour cell lines MCF-7 (Catalog no. 
86012803) and MDA-MB-231 (Catalog no. 92020424) were purchased from the European 
Collection of Cell Cultures (ECACC). Frozen vials of each cell line were rapidly thawed in a 
37oC water bath with gentle agitation, and placed immediately in 10 ml of fresh, pre-warmed, 
relevant growth media. 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 2-1 Morphology of human breast cancer and normal breast cell lines in culture. 
Cells were cultured and passaged when required as in section 2.2.1.3. Images were taken 
using an inverted microscope with 10x magnification. 
 
MDA-MB-231 MDA-MB-468 
MCF-7 MCF10
A 
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2.2.1.1 MCF7, MDA-MB-468 and MDA-MB-231 growth medium  
The complete medium for MCF7, MDA-MB-468 and MDA-MB-231 cells was Dulbecco’s 
modified eagle medium (DMEM) with phenol red and L-glutamine, supplemented with 10% 
fetal bovine serum (FBS), 100 units/ml penicillin, 0.1mg/ml streptomycin sulphate, and 
0.25µg/ml amphotericin B. 
2.2.1.2 MCF10A growth medium 
The complete medium for MCF10A cells consisted of Dulbecco’s modified eagle 
medium/F12 (DMEM/F12) with phenol red, supplemented with 100ng/ml cholera toxin, 0.5 
µg/ml hydrocortisone, 10µg/ml insulin, 20ng/ml epidermal growth factor (EGF), 100 µg/ml 
streptomycin, 100 units/ml penicillin, and 5% horse serum.  
2.2.1.3 Routine culture procedure of cell lines 
2.2.1.3.1  MCF7, MDA-MB-468 and MDA-MB-231 cell lines 
The cells were passaged routinely when they had reached approximately 70-80 % confluence. 
Cells were washed once with 1x phosphate buffered saline (PBS). 1ml of trypsin-EDTA was 
added, and then cells were incubated at 37oC for few minutes until they had detached. 
Trypsinisation was terminated by addition of 9ml of pre-warmed growth medium, and diluted 
into the required number of 75cm2 vented flasks. Under standard growth conditions, cells 
were passaged every three days at a ratio of 1:3. 
2.2.1.3.2 MCF10A cell line 
Cells were washed once with 1x PBS. 3 ml of trypsin-EDTA was added, and cells were 
incubated at 37oC for 15 minutes until they detached. Trypsinisation was terminated by 
addition of 12ml of pre-warmed growth medium. The cell suspension was transferred into a 
universal tube and then centrifuged at 300x g for 3 minutes. The pellet was resuspended in 
12ml of fresh, pre-warmed growth medium, and diluted into the required number of 75cm2 
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vented flasks. Under standard growth conditions, cells were passaged every three days at a 
ratio of 1:3.  
2.2.1.4 Long-term storage of cells in liquid nitrogen 
Cells were washed once with 1x PBS, and cells detached from the culture flask by 
trypsinisation and resuspended in fresh complete medium as described above. Cells were then 
centrifuged at 300xg for 3 minutes, medium discarded and the pellet resuspended in freezing 
medium (10% DMSO and 90% FBS) at a concentration of 1x106 cells/ml. Cells were split 
into cryo-vials, transferred to a cryo freezing container and kept in -80oC for 48 hours before 
transfer to liquid nitrogen for long-term storage.  
2.2.1.5 MTT cell viability assay  
MTT assay is used to measure cell viability by reduction of MTT (3-(4,5-dimethylthiazol-
2yl)-2,5-diphenyltetrazolium) to an insoluble, purple formazan metabolite by mitochondrial 
enzymes (Twentyman and Luscombe, 1987).  
On day 1 of the assay, a cell suspension was prepared for each cell line and diluted to a cell 
density of 5X104 per ml. Cells then were seeded into 96-well plates (5000 cells per well) and 
incubated overnight at 37oC to allow cell attachment. On day 2, the cells were observed under 
the microscope to ensure the required confluency (70-80%) had been achieved. If cells were 
at the correct confluence, medium was aspirated and replaced with serum-free medium 
(serum starving). On day 3, medium was aspirated and replaced with medium (with or 
without serum) containing test chemical or vehicle alone. For both CDCA and GW4064, 
dimethylsulfoxide was used as a solvent, with the final concentration not exceeding 0.1% 
DMSO. Following either 48 or 72 hours of drug exposure, medium was removed, stored at -
20°C for subsequent experiments. A 0.2mg/ml MTT solution was prepared in serum free 
medium and then added to each well and the cells incubated at 37oC for 20 minutes. After the 
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20 minutes, medium was removed 100% DMSO added to lyse the cells and solubilise the 
formazan metabolite. Plates were gently agitated and the absorbance measured at 540nm. 
2.2.1.6 Transwell migration assay  
Polycarbonate transwell inserts with 8μm pore size were placed into the wells of a 24-well 
plate to create two compartments. The permeable membrane of the inserts allows cells to 
migrate into the underside compartment. 650μl of medium with serum was added into the 
lower compartment. Into the upper compartment, 100μl of serum-free medium containing 
cells at a density of 1X106 per ml (100,000 cells) was added; where pre-exposure of the cells 
to compound was required, cells were exposed to 30 μM CDCA or 3μM GW4064 for one 
hour in serum free medium prior to seeding. Plates were incubated at 37oC for 72 hours to 
allow cell migration to occur, whereupon inserts were removed and the medium in the lower 
chamber removed and placed in 1.5 ml eppendorf tubes. To ensure counting of all migrated 
cells, 500 μl of 1x trypsin: EDTA was added into the lower compartments, the inserts 
replaced, and the plate incubated at 37oC for 30 minutes: Any cells freed through 
trypsinisation were added into the eppendorf tubes. Finally, cells were pelleted by 
centrifugation, resuspended in 100μl of serum-free medium and cells counted using a 
haemocytometer (Thomas et al., 2001).  
2.2.1.7 Transwell invasion assay 
The invasion assay tests not only cell motility, but also the ability to ‘invade’ through a semi-
permeable matrix resembling the extracellular matrix. The protocol is, in essence, the same as 
for the migration assay, with the exception that matrigel was used to represent the 
extracellular matrix. Matrigel was prepared as per the manufacturer’s instructions in pre-cold 
serum-free medium. 100μl of the diluted matrigel was added into the upper compartment of 
the transwell inserts and then plate was incubated at 37oC for one hour for gelling prior to 
seeding. The remaining protocol is as per section 2.2.1.6. 
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2.2.1.8 In vitro scratch wound healing assay 
In vitro wound healing assay is a complex event in which a scratch or a wound is generated in 
confluence cell monolayer, and then cells migrate in an oriented manner to close the scratch 
(Lampugnani, 1999).  
Cells were seeded at 5x105 cells/ml into ibidi culture inserts installed in µ-dishes and 
incubated at 37oC for 24 hours until reached confluency. The ‘wound’ in the cell monolayer 
was created by removing the inserts using sterile forceps. The cells were incubated in 
presence of IGF-1 (10ng/ml) or with FXR ligands CDCA (30µM) or GW4064 (3µM) or left 
untreated for 24 hours for MCF-7, MDA-MB-468 and MDA-MB-231 and for 16 hours for 
MCF10A. The dishes were photographed using inverted microscope at 10x magnification for 
time points 0-24 hours for MCF-7, MDA-MB-468 and MDA-MB-231 and 0-16 hours for 
MCF10A. The cell migration was assessed by measuring the remaining open area of the 
wound by Tscratch software.  
2.2.2 MMP activity measurement by gelatin zymography 
Getain zymography was used to examine the expression and activity of gelatinases; matrix 
metalloproteinase (MMP) -2 and -9 (Esteve et al., 1998, Passi et al., 1999). Conditioned 
media collected from cell lines exposed to test chemicals for 24 hours in serum free media 
(section 2.2.1.5) was diluted with either 5x or 2x sample buffer (Tris HCL pH6.8, glycerol, 
10% SDS, bromophenol blue), as required, and left for 10 minutes at room temperature.  
Using Bio-Rad Mini Protean Tetra cell apparatus, SDS polyacrylamide gel electrophoresis 
(PAGE) was prepared with 7.5% resolving gel (7.5% acrylamide, 0.2% bis-acrylamide, 0.1% 
SDS, 0.4M Tris-HCL pH8.8, 10% gelatin, 0.16% APS and 0.16% of TEMED) and 4% 
stacking gel (4% acrylamide, 0.1% bis-acrylamide, 0.1% SDS, 0.2M Tris-HCl pH6.8, 0.24% 
APS and 0.4% TEMED). 10µl multicolour protein ladder was loaded in the first well and 
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MMP-2/-9 standard was loaded in the last well as a positive control.  Samples then were 
loaded in the remaining wells and gel was run using SDS running buffer (25mM Tris–HCl 
pH8.3, 192mM glycine, 0.1% SDS) for one hour in ice at 250V. The gel was washed with 
2.5% Triton X-100 twice for 15 minutes to remove SDS and allow renaturation of the 
proteins. The gel was then incubated in developing buffer (1M Tris pH 7.5, 5M NaCl, 1M 
CaCl2, 2.5% Triton X-100 (in dH2O)) in a CO2-free incubator at 37
oC overnight. Next, 
developing buffer was removed and the gel was stained with coomassie blue (75% methanol, 
25% acetic acid, 1.25% (w/v) coomassie brilliant blue R) for 15-30 minutes. The gel then was 
destained by using coomassie destain solution and gentle agitation until clear bands were 
visible (75% methanol, 25% acetic acid), and gels scanned using Gene Genius BioImaging 
System (Syngene, Cambridge, UK). 
2.2.3 Gelatin cleavage assay 
Conditioned media collected from cell lines exposed to test chemicals for 48 or 72 hours 
(section 2.2.1.5) were mixed with 10mM MMP-2/MMP-9 substrate (2,4-Dinitrophenyl-Pro-
Leu-Gly-Met-Trp-Ser-Arg-OH) (Netzel-Arnett et al., 1991) or MMP-1/MMP-9 substrate 
(2,4-Dinitrophenyl-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(N-Me-Abz)-NH₂ [Cha = β-
cyclohexylalanyl; Abz = 2-aminobenzoyl (anthraniloyl)]) for MMP activity measurement 
(50:50 v/v). The plate then was placed on a mixer at room temperate for 20 minutes protected 
from light. Fluorescence was measured at 280 nm (λex), 405 nm (λem) (Nilsson et al., 2007). 
Readings were compared against a standard curve created using recombinant MMP-2 and 
MMP-9 proteins at varying concentrations, mixed with the substrate (50:50 v/v).  
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2.2.4 Western blotting 
2.2.4.1 Preparation of total protein extracts 
Cell lines were seeded in 6-well plates at a density of 6X105 per ml (600,000 cells per well) 
and incubated for 48 hours until cell confluence was greater than 75%. Next, medium was 
aspirated and cells serum-starved for 24 hours. Cells were exposed to GW4064 (3μM), 
CDCA (30μM) or vehicle (0.1% DMSO) for 24 hours at 37oC. Cells were harvested by 
washing once with 1x PBS, cell removal using cell scrapers, and centrifugation for a short 
spin (15 seconds). The supernatant was discarded and pellets were resuspended in radio 
immuno-percipitation assay (RIPA) buffer (1% igepal CA-630, 0.5% sodium deoxycholate, 
0.1% SDS, 1x PBS, 1x protease inhibitor cocktail) to initiate cell lysis. The cell lysates were 
stored in a -20oC until required. 
2.2.4.2 Measurement of total protein concentration 
Protein concentration was assessed using BCA (Bicinchoninic acid) protein assay kit. A 
standard curve was made using known concentration of bovine serum albumin (BSA; 0-1 
mg/ml). Standards were prepared in RIPA buffer to ensure no sample variation and measured 
as technical triplicates. 25µl of standard or sample were added per well along with 200µl of 
working reagent and mixed thoroughly by pipetting up and down. The plate was covered and 
incubated at 37°C for 30 minutes. Absorbance was measured at 540nm by 
Spectrophotometer, and protein concentrations calculated by comparison to the albumin 
standard curve.  
2.2.4.3 SDS polyacrylamide gel electrophoresis  
Gels consisting of a 4% stacking gel (4% acrylamide, 0.1% bis-acrylamide, 0.1% SDS, 0.2M 
Tris-HCl pH6.8, 0.24% APS and 0.4% TEMED) and a 10% resolving gel (10% acrylamide, 
0.3% bis-acrylamide, 0.1% SDS, 0.4M Tris-HCL pH8.8, 0.16% APS and 0.16% of TEMED) 
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were prepared. Stacking and resolving gels of 6%, 15% and %20 were used for lower 
molecular weight proteins. Once set, the gels were inserted into a BioRad Mini Protean Tetra 
cell apparatus running buffer (250mM Tris-HCl pH8.3, 1.9M glycine, 1% SDS). Samples 
were prepared by mixing with equal amounts of loading buffer (60mM Tris-HCl pH6.8, 12% 
glycerol, 2% SDS, 0.003% pyronin Y, 0.7M β-mercaptoethanol), followed by heat 
denaturation at 90oC for 10 minutes. Samples were loaded into the gel alongside a 
multicolour protein ladder and run at constant 150 mA until the dye front had reached the end 
of the gel (approximately 45 minutes).  
2.2.4.4 Protein immunoblot (Western blotting analysis) 
Nitrocellulose membrane, blotting papers and scotchbright pads were soaked in a tray 
containing transfer buffer (16mM Tris, 120mM glycine, 20% methanol)) for 10 minutes. For 
lower molecular weight proteins, microporous polyvinylidene difluoride (PVDF) membrane 
was used, and pre-soaked in 100% methanol for 10 minutes. The membrane cassette was 
placed black side down in a tray that contained transfer buffer and was assembled 
(scotchbright pad, two pieces of blotting paper, the gel, the membrane, two more pieces of 
blotting paper, scotchbright pad) ensuring no air bubbles between the gel and the membrane. 
The transfer tank was filled with transfer buffer, the cassette loaded, an ice pack added, and 
transfer carried out at constant 300 mA for 90 minutes.  
2.2.4.5 Immuno-detection 
The membrane was placed in a 50ml tube with the protein side facing inwards and incubated 
in 20ml of PBST (0.1% Tween-20 in PBS), containing 10% (w/v) Marvel milk powder for 1 
hour at room temperature on a rotary mixer. Following blocking, the membrane was washed 
three times with PBS-tween for 10 minutes on a rotary mixer. For detection of target proteins 
the membrane was first incubated overnight at 4oC with the primary antibody at the required 
concentration in 10% Marvel-PBST on a rotary mixer. The membrane then was washed with 
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PBS-tween three times for 10 minutes on a rotary mixer. Second, the membrane was 
incubated for one hour at room temperature with the horseradish peroxidase (HRP) 
conjugated secondary antibody at the required concentration in 5% Marvel-PBST. Third, the 
membrane was washed twice with PBST and once with PBS for 10 minutes at room 
temperature on a rotary mixer. Dilutions for specific antibodies are provided in table 2-4. 
Table 2-4 Primary and secondary antibodies used for immune detection 
Target/Size KDa Catalogue No.  Species/Isotype Optimised 
Dilutions 
Primary Antibodies 
MMP-2 
Pro/ Active  
72/ 63 
Sc-10736 Rabbit/ poly 1:200 
MMP-9 
Pro/ Active  
92/ 82 
Sc-10737 Rabbit/ poly 1:200 
FXR/ 59 Sc-13063 Rabbit/ poly 1:250/1:500 
TIMP-1/ 22 Sc-21734 Mouse/ mono 1:200 
TIMP-2/ 26 WH0007077M1 Mouse/ mono 1:200 
SHP/ 28 Sc-15283 Mouse/ mono 1:100 
Actin/ 42 A5441 Mouse/ mono 1:2000 
HRP Conjugated Secondary Antibodies 
Anti-rabbit Sc-2301 Goat 1:10000 
Anti-mouse Sc-2005 Goat 1:10000 
 
2.2.4.6 Chemiluminescent detection 
 First, the working solution for chemiluminescent detection was prepared by mixing equal 
amounts of the stable peroxide solution and the luminol/enhancer solution from the Pierce 
SuperSignal West pico chemiluminescent Kit. 2ml of the prepared reagent per 30cm² of 
membrane was poured onto the membrane surface and then incubated for 5 minutes at room 
temperature. Excess solution was drained and the membrane placed between two plastic sheet 
protectors, ensuring no air bubbles were present. The membrane was opposed to film and 
exposed for between 1 minute and 1 hour depending on the signal strength for each protein. 
The film was transferred into developer solution, and agitated while the bands developed. 
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Then film was then washed in water for 30 seconds, before fixing for at least 30 seconds. 
Finally, the film was rinsed with cold water and air-dried. 
2.2.4.7 Membrane stripping protocol for re-probing 
To enable re-probing of membranes with multiple primary antibodies, existing antibodies 
must be removed through chemical stripping. The membrane was placed in a 50ml tube with 
the protein side facing inwards and 10ml of mild stripping buffer (200mM glycine, 3.47mM 
SDS, 1% tween20, pH2.2) was added in order to remove the primary and the secondary 
antibodies. The blot was incubated for 30 minutes at room temperature on a rotary mixer, and 
then was washed in PBS-tween twice for 10 minutes. Membranes were then blocked and 
probed as before. Due to the loss of protein from the membrane during the stripping assay, 
membranes were stripped a maximum of three times (i.e. a membrane could be probed a 
maximum of four times). 
2.2.4.8 Densitometry of western blots 
Western blots images were scanned using the Gene Genius BioImaging System, and analysed 
using Image J. For background normalisation, an area on the film without band was used.  
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2.2.5 Quantitative real time polymerase chain reaction (qPCR) 
2.2.5.1 Preparation of total RNA extracts 
Cell samples were prepared as detailed in section 2.2.4.1, with the exception that the final 
pellet was resuspended in 500μl trizol reagent and stored at -80oC until required. For further 
processing, samples were defrosted at room temperature and the extraction protocol carried 
out according to manufacturer’s instructions. Briefly, in a fume hood, 100μl of chloroform 
was added into each sample, mixed by shaking vigorously by hand for 30 seconds and 
incubated at room temperature for 2-3 minutes. Samples were then centrifuged at 12000 x g 
for 15 minutes at 4oC, and the aqueous (upper) layer retained. Next, 250μl of isopropanol was 
added into each tube and samples were vortexed for 30 seconds and then incubated for 10 
minutes at room temperature. Tubes were centrifuged at 12000 x g for 10 minutes at 4oC, the 
supernatant removed and the RNA pellets washed with 500μl 75% ethanol. Samples were 
vortexed gently and then centrifuged at 7500 x g for 5 minutes at 4oC. Pellets were 
resuspended in 20μl of nuclease free water, heated for 10 minutes at 55oC and then kept in -
80oC until required. 
2.2.5.2 Measurement of total RNA concentration 
Total RNA concentration was measured using NanoDrop 2000 Spectrophotometer following 
the manufactures’ instructions. Potential salt and protein contamination was checked at this 
step as well. 
2.2.5.3 DNase treatment of RNA samples prior to RT-PCR 
Samples were treated with DNAse I prior to reverse transcription polymerase chain reaction 
(RT-PCR) to remove any contaminating genomic DNA that could confound the results. In a 
UV sterilizing PCR hood, 5µg of RNA was 2U DNAse I in DNase, reaction buffer, and 
incubated for 30 minutes at 37oC. To inactivate the DNase, 2µl stop solution (20mM EGTA) 
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was added and tubes placed back into the PCR machine for 10 minutes at 65oC. DNase 
treated mRNA samples kept in -80oC until used. 
2.2.5.4 Reverse transcription (cDNA synthesis)   
Complementary DNA (cDNA) was made by reverse transcription from the Dnase treated 
RNA samples. First, 9μl of each RNA sample was mixed with lμl of reaction mix (1.25mM 
dNTPs and 225ng random hexamers) and incubated at 65oC for 5 minutes to denature the 
secondary structure of the RNA, followed by immediate cooling in ice to allow the primer to 
anneal to the RNA strand. Next, the reverse transcription master mix (45% 5x RT buffer, 
22mM DTT, 11 % RNase OUT, 3% Superscript II) was added the reaction and incubated at 
25oC for 5 minutes and then at 55oC for 20 minutes to allow transcription step to occur. 
Finally, the reaction was heat inactivated by incubation at 75oC for 15 minutes to stop the 
enzyme and cDNA was stored at -20oC until use. A control containing no superscript II (RT 
minus) was included for all reactions, as this allowed for the control of contaminating 
genomic DNA in sample. 
2.2.5.5 Quantitative Polymerase Chain Reaction   
For detection of target or housekeeping genes, 2μl of the synthesised cDNA, equivalent to 
25ng input RNA, was added into 96-well PCR plate in duplicates in a UV sterilizing PCR 
hood. 18µl of qPCR reaction (500nM forward primer, 500nM reverse primer, 125nM probe, 
2X TaqMan universal PCR master mix with low rox) was then added. The plate was sealed 
and centrifuged for 1 minute at 1000 rpm. Plate then was placed into the PCR machine. Plates 
were run on an ABI 7000HT sequence detection system using the following program: 50°C 2 
minutes, 95°C 15 minutes, 95°C 15secs, 60°C 1min over 40 cycles and data interpreted using 
the ABI proprietary software. 
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2.2.6 ELISA for quantification of MMPs and TIMPs concentrations 
Enzyme-linked immunosorbent assay (ELISA) was used to quantify the concentrations of 
MMPs and TIMPs in conditioned (chemical exposed) medium. All reagents and standards 
were prepared according to the manufacturer’s instructions. Briefly, conditioned media from 
previous experiments was used as samples, and these were pipetted in duplicates in ELISA 
plates and incubated for 2.5 hours at room temperature. Solutions were discarded and the 
plate washed four times with wash solution (PBS), ensuring complete removal of the liquids 
in each step by blotting the plate against clean paper towels. Biotinylated detection antibody 
was added at the required concentration, and the plate incubated for 1 hour at room 
temperature with gentle shaking. Following, four washes as before, HRP-conjugated 
streptavidin solution was added to each well and the plate was incubated for 45 minutes at 
room temperature with gentle shaking. Following, four washes as before, TMB substrate 
reagent (This reagent is a ready-to-use peroxidase substrate containing 3,3’,5,5’ 
tetramethylbenzidine (TMB) in a mildly acidic buffer) was added to each well, and incubated 
for 30 minutes in the dark. Stop solution (0.2M sulfuric acid) was added to each well and 
colour intensity measured at 450nm immediately. Protein concentration was compared to a 
standard curve generated from recombinant proteins for each target protein.  
2.2.7 Statistical analysis 
Data are expressed as mean ± SEM from three independent experiments, unless otherwise 
stated. Parametric and nonparametric statistical analyses were performed, compared to 
control. *P<0.05, **p< 0.01, ***p<0.001, ****p<0.0001 were considered statistically 
significant. The statistical tests were performed using GraphPad Prism software v6.0. 
 70 
 
 
 
 
 
 
 
 
 
3 Characterisation of cell lines 
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 Introduction 
The metastatic spread of mammary carcinoma is one of the main causes of mortality in 
women with breast cancer (BreastCancerCampaign, 2011). A key stage in metastasis is the 
degradation of the extracellular matrix, creating flexibility in the cellular microenvironment 
and allowing cancerous cells to spread to distant organs and form the secondary tumours 
(Bagnoli et al., 2010). Matrix metalloproteinases are a family of zinc-dependant 
endopeptidases that have the capability to degrade type IV collagen, which is a major 
component of the extracellular matrix, thereby enabling tumours cells to invade and spread 
(Bartsch et al., 2003b, Jones and Walker, 1997, Davies et al., 1993). As such, it is perhaps not 
surprising that in almost every type of malignancy, induction of MMPs activity is associated 
with poor patient prognosis (Rundhaug, 2003). This is the case in breast cancer, where MMP 
overexpression and the associated increase in activity has been positively associated with 
advanced breast cancer, contributing to an aggressive, metastatic phenotype (Heppner et al., 
1996, Wang et al., 1997).  
The MMP family of zinc-dependent endopeptidases is composed of 23 members in humans, 
and these can be roughly divided into secreted and membrane-associated family members. 
Their  primary role in the body is the degradation of extracellular components such as 
collagen (Woessner, 1991), but they also interact with specific signalling molecules such as 
Fas ligand (Kayagaki et al., 1995) and cytokines (e.g. TGFB (Yu and Stamenkovic, 2000)). 
As such, they have been linked with a number of disease states, including cardiovascular 
(Griffioen and Molema, 2000) disease, nervous systems pathologies (Yong et al., 2001), 
endometriosis (Giudice and Kao, 2004), and tumour metastasis (Deryugina and Quigley, 
2006). Initially MMPs are secreted in inactive forms and called zymogens. So they need to be 
activated before being able to degrade the extracellular matrix (Vizoso et al., 2007, Castro et 
al., 2011). MMPs are activated by other MMPs or by serine proteases (Vizoso et al., 2007). 
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Production of MMPs is controlled and they are not created until required (Rundhaug, 2003). 
Moreover, the activity of the MMPs is powerfully regulated by endogenous inhibitors that are 
called tissue inhibitors of metalloproteinases (Figueira et al., 2009). There are four different 
endogenous inhibitors of MMPs and they include TIMP-1, TIMP-2, TIMP-3 and TIMP-4 
(Vizoso et al., 2007, Visse and Nagase, 2003, Gorman et al., 2011). TIMP-1 inhibits MMP-9 
and TIMP-2 inhibits MMP-2 (Stetler-Stevenson et al., 1989, Wilhelm et al., 1989, Avolio et 
al., 2005). Figure 3.1 
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Figure 3-1 The metalloproteinase system. Activity of MMPs is regulated at different 
positions which include transcription, translation, activation, and inactivation. First MMPs 
secreted as inactive forms that need cleaving pro-peptide region in order to be active. This 
occurs via autocatalysis, other MMPs like MT-MMP, thrombin, or reactive oxygen species in 
case of MMP-2. TIMPs bind to the active site of MMP, thus blocking the active proteases by 
creating an inactive ‘TIMP-MMP complex’. Control of MMP activity depends on the balance 
between the MMP and TIMPs (Libby and Lee, 2000). 
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The potentiality of neoplastic cells to invade and metastasize is the result of the irregularity in 
balance of proteases/inhibitors activities (Figueira et al., 2009). A great interest has been 
grown in developing novel methods to inhibit the MMPs as there is a direct relation between 
the expression of MMPs and the invasiveness of the tumours that was shown in many human 
cancers like breast, prostate, stomach, colon, ovary, thyroid and oral squamous cell cancers 
(Stetler-Stevenson et al., 1996).  
Many studies have implicated two MMPs as being central to the metastatic progression in 
breast cancer: MMP-2 (also known as gelatinase A) and MMP-9 (gelatinase B) (Kohrmann et 
al., 2009, Bagnoli et al., 2010, Davies et al., 1993, Giannelli et al., 2002). Both MMP-2 and 
MMP-9 are highly expressed in breast tissue (Bartsch et al., 2003b). A study by Daniele et al. 
showed that this expression of MMP-2 and -9 was significantly higher in metastatic breast 
cancer comparing to non-metastatic cancer  patients (Daniele et al., 2010). The mechanisms 
by which MMP-2 and MMP-9 may cause  metastasis have not yet been fully defined 
(Incorvaia et al., 2007). However, Somiari et al showed that serum MMP-2 and -9 may have 
a potential role as biomarkers for breast cancer classification, as they demonstrated that total 
activities of MMP-2 and -9 are higher in benign compared to aggressive cancer (Somiari et 
al., 2006). It should be noted that this finding is somewhat contradictory to the current 
thinking, where increased MMP expression is thought to be associated with an increased 
metastatic potential through enhanced ECM re-modelling; further work must be undertaken 
to fully explore this potential.  
As discussed in the introduction, the farnesoid-X receptor is a nuclear receptor predominantly 
expressed in the liver and intestine, where it is involved in with bile homeostasis (Journe et 
al., 2008, Journe et al., 2009). Recently, further FXR functions other than its role in 
metabolism have been identified in many nonenterohepatic tissues, including potential roles 
in breast cancer. Swales et al, 2006, showed expression of FXR in breast malignancies at 
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higher levels than in normal breast, where it was also expressed. Moreover, they 
demonstrated that the FXR agonists CDCA and GW4064 killed breast cancer cells through 
induction of apoptosis (Swales et al., 2006). This potential chemoprotective action was 
further supported by Modica et al, who demonstrated that FXR activation protected against 
intestinal carcinogenesis in vivo (Modica et al., 2008). 
In addition to its potential role as a pro-apoptotic signal, FXR activation has also been 
associated with alterations in extracellular matrix remodelling, and in particular interaction 
with the MMPs. In vascular tissues, evidence for an  anti-metastatic action of FXR agonists 
was provided by Yoyo et al, who demonstrated that FXR activation by 6-ethyl 
chenodeoxycholic acid (6-ECDCA) inhibited MMP-2 and -9 activities, and decreased their 
mRNA levels (Yoyo T.Y. Li et al., 2006). Similarly, FXR was demonstrated to be 
overexpressed in pancreatic cancers, and guggulsterone-mediated FXR inhibition resulted in 
decreased proliferation and metastatic behaviour in pancreatic cell lines (Lee et al., 2011, 
Macha et al., 2013). Finally, the role of FXR modulation in liver cancer has been studied: 
Fiorucci et al, demonstrated that activation of FXR by 6-ECDCA decreased the expression of 
the MMP inhibitors TIMP-1 and -2 by 60 to 70%, respectively, resulting in an increased in 
activity of MMP-2 by 2 folds in hepatic stellate cells (Fiorucci et al., 2005), while Deuschle 
et al demonstrated FXR-meditated inhibition of liver tumour growth and metastasis in mouse 
xenograft (Deuschle et al., 2012).  
These results support the hypothesis that FXR plays an important role in controlling tumour 
growth and metastatic potential, and agonists of this receptor may represent potential 
therapeutic agents in this area. To understand the potential role of FXR activation in the 
context of breast cancer, it is important to study breast tumour models. Therefore, the aim of 
this study was to evaluate whether FXR agonists GW4064 and CDCA affect the cell viability 
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and regulate the expression of MMP-2 and -9 and TIMP-1 and -2 in breast cancer and normal 
breast.  
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 Results 
3.2.1 FXR expression in breast cancer cell and normal breast tissue 
In this experiment, FXR expression was confirmed in all the breast cancer and normal breast 
cell lines used in this project by western blotting (Figure 3.2). 
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Figure 3-2 Expression of FXR in MCF-7, MDA-MB-468, MDA-MB-231 and MCF10A. 
Western blots findings for FXR expression shown as a representative image (upper panel) 
with corresponding β actin loading control (lower panel). Membranes of the previous MMP-2 
& -9 western blotting were stripped using stripping buffer and incubated for 30 minutes. 
Then membranes were reprobed with anti-rabbit FXR primary antibody (dilution 1:250) 
using same protocol from blocking stage as described in 2.2.4.7. Three independent protein 
extracts sets were treated with FXR ligands for other experiments and also used for FXR 
expression. N=3 for all cell lines.  
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3.2.2 Cytotoxic assays  
3.2.2.1 Measuring the effects of FXR agonists on cell viability using the MTT assay 
In the present study, the MTT assay was used to assess the cytotoxicity of the FXR agonists 
CDCA and GW4064. The MTT assay is a simple colorimetric assay that measures 
mitochondrial function as a surrogate marker of cell viability (Twentyman and Luscombe, 
1987); as such, it is ideal to identify both cytotoxic and proliferative effects of chemicals, 
which is a distinct advantage in the current study. Cell viability following exposure to either 
CDCA, GW4064 or vehicle control was determined for four breast cell lines with differing 
phenotypes: 
A) MCF-7 (ER+ phenotype)  
B) MDA-MB-468 (ER, PR, HER-2: Triple negative phenotype) 
C) MDA-MB-231 (ER, PR, HER-2: Triple negative phenotype)  
D) MCF-10A (normal phenotype) 
Treating triple negative breast cancer is particularly challenging, in part due to the fact that 
multiple molecular landscapes are included in this group, and hence two cell lines 
representing this phenotype were used. The MDA-MB-468 cell line is derived from a basal-
like tumour, whereas the MDA-MB-231 cell line is derived from a mesenchymal-like triple 
negative tumour (Lehmann et al., 2011). Cells were treated with increasing concentrations of 
FXR ligands (CDCA 10, 30, 100, 300μM, and GW4064 1, 3, 10, 30μM), or vehicle control 
(0.1% DMSO) for 48h and 72h. Cells were grown under both 10% serum and serum-free 
conditions as described in section 2.2.1.5. 
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3.2.2.2 Cell viability of MCF-7 cells following exposure to FXR ligands  
In the MCF-7 breast cancer cell line both FXR ligands, GW4064 and CDCA, elicited a dose- 
and time- dependent cytotoxicity. In the case of the low affinity endogenous ligand CDCA, a 
30% reduction in MTT conversion was observed after 48h exposure at the maximal 
concentration used (300µM; Figure 3.3). This Figure increased to 40% following 72 hours 
exposure to 300µM CDCA (Figure 3.3). No significant difference in cytotoxicity was 
observed between serum-free and serum-supplemented conditions. 
The high affinity FXR ligand GW4064 elicited a maximal reduction in mitochondrial enzyme 
activity of approximately 40% after 48 hours both serum-free and serum-supplemented 
conditions (45% and 40%, respectively). However, following 72 hours exposure to 10µM 
GW4064 a statistically significant difference between cells grown in serum-supplemented 
medium versus serum-free medium was observed: In the former case, a maximal 15% 
reduction was observed, while in serum-free medium this increased to 50% (Figure 3.3). 
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Figure 3-3 Cell viability for MCF-7 within 48h and 72h treatments with FXR ligands 
determined by MTT assay. Cell viability was assessed after treating human breast cancer 
cell line MCF-7 with vehicle control DMSO and FXR ligands CDCA & GW4064 at a range 
of concentrations for 48h and 72h under 10% serum and serum free conditions. Mean ± SEM, 
n=9, *p<0.05, **p< 0.01, ***p<0.001, ****p<0.0001 compared to control by repeated 
measures one-way ANOVA (Bonferroni’s multiple comparisons test). Parametric statistical 
analysis was selected because there no evidence in the data to indicate Gaussion distribution 
could not be assumed, all data points are within 1 standard deviation of the mean.  
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3.2.2.3 Cell viability of MDA-MB-468 cells following exposure to FXR ligands  
In the MDA-MB-468 breast cancer cell line both FXR ligands, GW4064 and CDCA, elicited 
a dose- and time- dependent cytotoxicity. In the case of the low affinity endogenous ligand 
CDCA, a 45% reduction in MTT conversion was observed after 48h exposure at the maximal 
concentration used (300µM; Figure 3.4). This concentration elicited 30% reduction following 
72h exposure to 300µM CDCA in serum-supplemented conditions (Figure 3.4). In the serum-
free conditions, CDCA elicited a statistically significant reduction in a dose dependant 
manner.  
The high affinity FXR ligand GW4064 elicited a maximal reduction in mitochondrial enzyme 
activity of approximately 75% after 48 (Figure 3.4) and 95% after 72 hours (Figure 3.4) in 
serum-free conditions. A statistically significant difference between cells grown in serum-
supplemented medium versus serum-free medium was observed: In the former case, no 
reduction was observed.  
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Figure 3-4  Cell viability for MDA-MB-468 within 48h and 72h treatments with FXR 
ligands determined by MTT assay. Cell viability was assessed after treating human breast 
cancer cell line MDA-MB-468 with vehicle control DMSO and FXR ligands CDCA & 
GW4064 at a range of concentrations for 48h and 72h under 10% serum and serum free 
conditions. Mean ± SEM, n=9, * p<0.05, **p< 0.01, ***p<0.001, ****p<0.0001 compared to 
control by repeated measures one-way ANOVA (Bonferroni’s multiple comparisons test). 
Parametric statistical analysis was selected because there no evidence in the data to indicate 
Gaussion distribution could not be assumed, all data points are within 1 standard deviation of 
the mean.  
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3.2.2.4 Cell viability of MDA-MB-231 cells following exposure to FXR ligands  
In the MDA-MB-231 breast cancer cell line both FXR ligands, GW4064 and CDCA, elicited 
a dose- and time- dependent cytotoxicity. In the case of the low affinity endogenous ligand 
CDCA, a 40% reduction in MTT conversion was observed after 48h exposure at the maximal 
concentration used (300µM; Figure 3.5). This figure decreased to 30% following 72h 
exposure to 300µM CDCA (Figure 3.5). A significant difference in cytotoxicity was 
observed between serum-free and serum-supplemented conditions. 
The high affinity FXR ligand GW4064 elicited a maximal reduction in mitochondrial enzyme 
activity of approximately 25% after 48 hours in serum-supplemented conditions, and 
reduction on concentration dependant manner in serum free conditions. However, following 
72 hours exposure to GW4064 a statistically significant difference between cells grown in 
serum-supplemented medium versus serum-free medium was observed: In the former case, 
no reduction was observed, while in serum-free medium this increased to 50% (Figure 3.5).      
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Figure 3-5 Cell viability for MDA-MB-231 within 48h and 72h treatments with FXR 
ligands determined by MTT assay. Cell viability was assessed after treating human breast 
cancer cell line MDA-MB-231 with vehicle control DMSO and FXR ligands CDCA & 
GW4064 at a range of concentrations for 48h and 72h under 10% serum and serum free 
conditions. Mean ± SEM, n=12 (With CDCA), n=9 (With GW4064), * p<0.05, **p< 0.01, 
***p<0.001, ****p<0.0001 compared to control by repeated measures one-way ANOVA 
(Bonferroni’s multiple comparisons test). Parametric statistical analysis was selected because 
there no evidence in the data to indicate Gaussion distribution could not be assumed, all data 
points are within 1 standard deviation of the mean. 
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3.2.2.5 Cell viability of MCF10A cells following exposure to FXR ligands  
In the MCF10A breast cancer cell line both FXR ligands, GW4064 and CDCA, elicited a 
dose- and time- dependent cytotoxicity. In the case of the low affinity endogenous ligand 
CDCA, a 65% reduction in MTT conversion was observed after 48h exposure at the maximal 
concentration used (300µM; Figure 3.6). This figure increased to 80% following 72h 
exposure to 300µM CDCA in serum free conditions and decreased to 40% in serum- 
supplemented condition (Figure 3.6). No significant difference in cytotoxicity was observed 
between serum-free and serum-supplemented conditions. 
The high affinity FXR ligand GW4064 elicited a maximal reduction in mitochondrial enzyme 
activity of approximately 95% after 48 hours in serum-free and no reduction was observed in 
serum-supplemented conditions. However, following 72 hours exposure to 3µM GW4064, 
50% reduction in MTT conversion was observed in serum free conditions. However, in 
serum-supplemented medium, proliferation was observed (Figure 3.6).  
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Figure 3-6 Cell viability for MCF-10A within 48h and 72h treatments with FXR ligands 
determined by MTT assay. Cell viability was assessed after treating human normal breast 
cell line MCF-10A with vehicle control DMSO and FXR ligands CDCA & GW4064 at a 
range of concentrations for 48h and 72h under 10% serum and serum free conditions. Mean ± 
SEM, n=9, * p<0.05, **p< 0.01, ***p<0.001, ****p<0.0001 compared to control by repeated 
measures one-way ANOVA (Bonferroni’s multiple comparisons test). Parametric statistical 
analysis was selected because there no evidence in the data to indicate Gaussion distribution 
could not be assumed, all data points are within 1 standard deviation of the mean. 
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3.2.3 Biochemical assays 
3.2.3.1 Measuring the mRNA levels of MMP-2, -9, TIMP-1 and -2 within breast cancer 
cells using qRTPCR 
Having confirmed the cytotoxic potential of the FXR ligands CDCA and GW4064 on breast 
cancer cell lines, I next examined the potential role of FXR activation in tumour cell invasion 
and migration. Experiments in prostate and liver cells have suggested that FXR activation 
leads to alteration in MMP-dependent ECM remodelling (Fiorucci et al., 2005, Lee et al., 
2011, Deuschle et al., 2012, Macha et al., 2013), an important step in the growth and invasion 
process of tumours (Matrisian, 1990). Therefore, the expression levels of MMP-2 and MMP-
9, the major MMPs present in breast tissue, were assessed at the transcript, protein and 
activity levels. 
An important regulator of MMP activity in vivo are the tissue inhibitor of metalloproteinase 
(TIMP) family of proteins. To examine if any FXR-mediated effects on tumour cell growth 
and metastasis were mediated indirectly through altered TIMP activity rather than directly 
through interaction with MMPs, I also assessed the level of TIMP-1 and TIMP-2 at both the 
transcript and protein levels.  
Based upon the cytotoxicity data, it was decided to focus on the MCF-7 and MDA-MB-468 
cell lines, which represent ER+ and triple negative phenotypes, respectively. Total RNA 
extracts was prepared for MCF-7 and MDA-MB-468 breast cancer cells after exposure to the 
FXR agonists CDCA (30μM) and GW4064 (3μM); these concentrations were chosen as they 
elicited mild cytotoxicity, but not so much that subsequent analysis was compromised.  
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3.2.3.1.1 Expression of MMP-2 and -9 in MCF-7 and MDA-MB-468 at the transcript 
level 
MMP-2 transcript levels were detected in MDA-MB-468 cells, but not in MCF-7 cells. 
Exposure of these MDA-MB-468 cells to the FXR agonists CDCA (30µM) or GW4064 
(3µM) for 24 hours did not cause any alteration in transcript levels. MMP-9 was detected in 
both MCF-7 and MDA-MB-468 cells, but again there was no effect on transcript levels 
following 24 hours exposure to CDCA (30µM) or GW4064 (3µM) (Figure 3.7). 
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Figure 3-7 FXR ligands appeared to have no effect on MMP-2 and MMP-9 mRNA 
levels within MCF-7 and MDA-MB-468 breast cancer cells. MMP-2 was not detected at a  
mRNA level in MCF-7 cells. cDNA was synthesized from 5µg RNA extracts from MCF-7 
and MDA-MB-468 cells after treatment with FXR ligands CDCA (30µM) or GW4064 (3µM) 
for 24h. Specific probes and primers for MMP- 2 and -9 were used for real time PCR. Mean 
± SEM, n=3 in duplicates compared to control by repeated measures one-way ANOVA 
(Bonferroni’s multiple comparisons test). Parametric statistical analysis was selected because 
there no evidence in the data to indicate Gaussion distribution could not be assumed, all data 
points are within 1 standard deviation of the mean.  
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3.2.3.1.2 Expression of TIMP-1 and -2 in MCF-7 and MDA-MB-468 at the transcript 
level 
To complement measurement of MMP-2 and MMP-9, the levels of their associated 
endogenous inhibitors, TIMP-1 and TIMP-2 were also measured. Both TIMP-1 and TIMP-2 
transcripts were detected in MCF-7 and MDA-MB-468 cell lines. However, 24 hours 
exposure to the FXR agonists CDCA (30µM) and GW4064 (3µM) did not cause any 
significant change in these levels (Figure 3.8). 
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Figure 3-8 FXR ligands appeared to have no effect on TIMP-1 and -2 mRNA levels 
within MCF-7 and MDA-MB-468 breast cancer cells. cDNA was synthesized from 5µg 
RNA extracts from MCF-7 and MDA-MB-468 cells after treatment with FXR ligands CDCA 
(30µM) or GW4064 (3µM) for 24h. Specific probes and primers for TIMP-1 and -2 were 
used for real time PCR. Mean ± SEM, n=3 in duplicates compared to control by repeated 
measures one-way ANOVA (Bonferroni’s multiple comparisons test). Parametric statistical 
analysis was selected because there no evidence in the data to indicate Gaussion distribution 
could not be assumed, all data points are within 1 standard deviation of the mean.  
For MCF-7, the baseline (DMSO vehicle control) average Cts were MMP-9 31, TIMP-1 
25.4, TIMP-2 28.53 and GAPDH 22.64 (for MMP-9 and TIMP-2) and GAPDH 21.3 (for 
TIMP-1). Therefore the average baseline deltaCts used to calculate fold induction were 
MMP-9 8.38, TIMP-1 4.1, TIMP-2 5.9. For MDA-MB-468, the baseline (DMSO vehicle 
control) average Cts were MMP-2 33.25, MMP-9 35.45, TIMP-1 30.5, TIMP-2 29.9 and 
GAPDH 21.71. Therefore the average baseline deltaCts used to calculate fold induction were 
MMP-2 11.5, MMP-9 13.8, TIMP-1 8.8, TIMP-2 8.16.  
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3.2.3.2 Measuring the protein levels of MMP-2, -9, TIMP-1 and -2 within breast cancer 
cells using western blotting 
Given that there is extensive evidence that increased MMP activity can be achieved through 
post-translational modification as well as through the transcriptional process, the protein 
levels of MMPs and TIMPs were next investigated. Protein extracts were prepared from 
MCF-7, MDA-MB-468, MDA-MB-231 and MCF10A cells following 24 hours exposure to 
the FXR agonists CDCA (30μM) and GW4064 (3μM). 
 
3.2.3.2.1 Effect of FXR activation on MMP-2 and -9 protein levels in breast cancer cells 
Both MMP-2 and MMP-9 protein was detected in MCF-7 and MDA-MB-468 cells under 
basal conditions. This is divergent from the pattern seen at the transcript level, where MMP-2 
was not detected at the transcript level in MCF-7 cells. Upon FXR activation by either CDCA 
(30μM) or GW4064 (3μM), no statistically significant change in protein levels of MMP-2 
and MMP-9 were detected compared to control (Figure 3.9). A trend towards increased 
MMP-9 expression in MCF-7 cells is observed following FXR activation; however, this is 
statistically non-significant and would require further independent repeats, increasing the 
power of the analysis, to determine if the effect is real or not.  
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Figure 3-9 FXR ligands have no effect on MMP-2 &-9 protein levels within breast 
cancer cells. Results shown as a representative blot image (middle panel) with corresponding 
β actin loading control (lower panel) and the densitometric ratios of MMP-2 &-9 to β actin 
(upper panel). MMP-2 (72Kda) & -9 (92Kda) protein levels did not change after treatment 
with FXR ligands CDCA and GW4064 in MCF7 & MDA-MB-468 cells. Both cell lines were 
incubated with FXR ligands to a final concentration CDCA 30µM and GW4064 3µM for 24h 
prior to protein extraction. Amount of protein samples (range 30-50µg) were loaded.  MMP-2 
&-9 were detected using anti-rabbit MMP-2 &-9 primary antibodies (dilution 1:200) and 
secondary antibody (dilution 1:10000). Data presented are normalised to β actin loading 
control. Mean ± SEM, n=3 compared to control by repeated measures one-way ANOVA 
(Bonferroni’s multiple comparisons test). Parametric statistical analysis was selected because 
there no evidence in the data to indicate Gaussion distribution could not be assumed, all data 
points except MMP-9, CDCA for MCF-7, are within 1 standard deviation of the mean.  
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3.2.3.2.2 Effect of FXR activation on TIMP-1 and -2 protein levels in breast cancer 
cells 
TIMP-1 (23 Kda) and TIMP-2 (24 Kda) were not detected using 12.5 %, 6% gels in both 
MCF-7 and MDA-MB-468 protein extracts (same extracts for MMP-2 and -9 detection in 
(3.2.3.2), and β actin showed that protein loading was successful.  
3.2.3.2.2.1 Optimization of TIMPs antibodies  
An important post-translational control mechanism for the activity of MMPs is their 
interaction with TIMP protein family members (Matrisian, 1990, Woessner, 1991). 
Therefore, expression of TIMP-1 and TIMP-2, the family members that regulate MMP-2 and 
MMP-9 activity, were measured in breast cancer cell lines.  
Unfortunately, despite prolonged optimisation, it was not possible to achieve satisfactory 
immunoblots using antibodies directed against TIMP-1, and hence only data for TIMP-2 
expression is presented. As demonstrated in figure 3.10, the TIMP-2 antibody was able to 
detect the positive control (recombinant TIMP-2). Under basal conditions, TIMP-2 
expression was minimal in MDA-MB-231 cells, and undetectable in MCF-7 cells. Treatment 
of MCF-7 cells with All-Trans Retinoic Acid (ATRA), a known inducer of TIMP-2 
expression (Dutta et al., 2009) also failed to produce an immunoreactive band.  
 
 
 
 
 
 96 
 
 
 
Bands from left: 
A) TIMP STD 
B) MDA-MB-231 untreated 
C) MCF-7 untreated 
D) MCF-7 treated with ATRA 
Figure 3-10 Optimization of TIMP-2 antibody in MDA-MB-231 and MCF-7. Results 
shown as a representative blot image (upper panel) with corresponding β actin loading 
control (lower panel). Protein sample of MDA-MB-231(54µg), MCF-7 (50µg) and MCF-7 
treated with ATRA (50µg) were loaded into 15% gel. Only basal level of TIMP-2 (24 Kda) 
was detected using primary anti-mouse antibody (1:200 dilution) and secondary antibody 
(dilution 1:10000) in MDA-MB-231, but not detected in MCF-7 or MCF-7 treated with 
ATRA. Recombinant TIMP-2 standard was included as the positive control.  
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3.2.3.3 ELISA 
3.2.3.3.1 Measurement the protein concentration of MMP-2 &-9 and TIMP-1&-2 
secreted to the media of MCF-7 and MD-MB-468 cell lines 
As noted in the introduction, MMP activity can be modulated at both the transcriptional 
(Page-McCaw et al., 2007) and post-translational level (Page-McCaw et al., 2007). 
Measurements at the transcript and protein levels detects changes in absolute levels, but are 
unable to assess changes in activity due to altered localisation, or some post-translational 
modifications. For MMPs, an important regulatory step is their secretion from cells, placing 
them in direct contact with their ECM-component substrates. Hence, we used ELISA to 
assess both MMP and TIMP proteins in media from control, CDCA (30μM) and GW4064 
(3μM) exposed MCF-7 and MDA-MB-468 breast cancer cell lines.  
As shown in Figure 3.11, MMP-2 and MMP-9 were present in conditioned medium from 
MCF-7 cells exposed to control only. It should be noted that considerable inter-sample 
variability existed in the MMP-2 (100-fold). This is unlikely to be a sampling error as the 
MMP-9 assay from the same samples showed only a 50-fold variation. Following exposure to 
GW4064 (3μM) for 24 hours, conditioned media from MCF-7 cells demonstrated a 
statistically significant increase in MMP-2, while MMP-9 was unchanged. TIMP-1 and 
TIMP-2 were detected in conditioned medium from control MCF-7 cells. TIMP-2 levels were 
low (average 850pg/ml), and 2-fold lower, on average, than TIMP-1 levels. This is consistent 
with the non-detection of TIMP-2 protein within MCF-7 cells. 
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Figure 3-11 FXR ligands have no effect on MMP-2&-9, TIMP-1&-2 protein levels 
secreted from MCF-7 cells. Commercial ELISA kits (Abcam) were used with conditioned 
media collected from western blotting experiments for MCF-7 to detect the amount of the 
MMP and TIMP proteins that were secreted. Mean ± SEM, TIMP1 n=3, TIMP2 n=4, MMP-2 
n=5, MMP9 n=5 all in duplicates, and data analysis was performed by Friedman test with 
Dunn’s multiple comparisons test to compare treatment groups to control. Non-parametric 
statistical analysis was selected because of the large standard deviation in some of the 
datasets and differences in standard deviation between treatment groups which indicate 
Gaussion distribution can not be assumed. Repeated measures analysis was chosen because 
data within an individual experiment was matched.  
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For medium conditioned by MDA-MB-468 cells, MMP-2 and MMP-9 were detectable, and 
were present at similar levels to that seen in MCF-7 conditioned medium (approximately 
100ng/ml). As seen with MCF-7 cells, there was greater variability in MMP-2 levels between 
samples (100-fold) compared to MMP-9 (50-fold). Use of media conditioned by MDA-MB-
468 cells exposed to either CDCA (30μM) or GW4064 (3μM) for 24 hours did not result in 
any significant increase in MMP-2 or MMP-9 levels. TIMP-1 and TIMP-2 were detectable in 
medium conditioned by MDA-MB-468 cells, with TIMP-1 being approximately 10-fold 
higher. Again, there was no significant increase in the expression in medium conditioned by 
cells exposed to either CDCA (30μM) or GW4064 (3μM) for 24 hours (Figure 3.12).  
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Figure 3-12 FXR ligands have no effect on MMP-2&-9, TIMP-1&-2 protein levels 
secreted outside the MDA-MB-468 cells. Commercial ELISA kits (Abcam) were used with 
conditioned media collected from western blotting experiments for MDA-MB-468 to detect 
the amount of the MMP and TIMP proteins that were secreted. Mean ± SEM, TIMP1 n=3, 
TIMP2 n=4, MMP-2 n=4, MMP9 n=5 all in duplicates, and data analysis was performed by 
Friedman test with Dunn’s multiple comparisons test to compare treatment groups to control. 
Non-parametric statistical analysis was selected because of the large standard deviation in 
some of the datasets and differences in standard deviation between treatment groups which 
indicate Gaussion distribution can not be assumed. Repeated measures analysis was chosen 
because data within an individual experiment was matched.  
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 Discussion 
There has been considerable debate around the role of nuclear receptors in non-classical 
tissues, and whether such expression is of biological importance (De Gottardi et al., 2004, De 
Gottardi et al., 2006, Kim et al., 2007b, Journe et al., 2008, Modica et al., 2008, Maran et al., 
2009, Lee et al., 2011, Zhang et al., 2012). In the case of FXR, such non-classical tissues 
include the breast and vasculature (Bishop-Bailey et al., 2004, Swales et al., 2006). In both 
cases, it could be hypothesised that such expression is important as a sensing mechanism for 
primary bile acids, such as CDCA. These are usually present in the blood at concentrations in 
the low micromolar range, although considerable inter-individual variability exists (McRae et 
al., 2010). Due to the highly fatty nature of breast tissue, concentrations of lipophilic 
compounds such as primary bile acids (LogP = 3.01; (Tetko et al., 2005)) often approach 
unity with the plasma concentration.   
I selected MCF-7, MDA-MB-468, MDA-MB-231 and MCF10A cell lines as an in vitro 
model system to characterize the role of FXR in mammary carcinoma as we and others 
(Swales et al., 2006, Journe et al., 2008, Journe et al., 2009) have shown that FXR is 
expressed in them by western blotting and immunohistochemial analysis. In addition, these 
cell lines represent different sub-types of breast cancer: MCF-7 cells are oestrogen receptor 
positive and represent a non-aggressive phenotype, while MDA-MB-468 cells are triple 
negative and represent a highly aggressive phenotype.   
The findings presented in this chapter are consistent with an absence of mechanistic interplay 
between FXR and the MMP/TIMP network. MMP and TIMP expression was confirmed at 
both the transcript and protein in the breast cancer cells MCF-7 and MDA-MB-468. 
However, these levels were not altered by treatment of cells with the FXR agonists CDCA or 
GW4064. Examination of the MCF-7 and MDA-MB-468 secretome also identified both 
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MMPs and TIMPs activity in conditioned media, demonstrating that these proteins were 
secreted to their eventual site of action, the extracellular matrix (Woessner, 1991, Massova et 
al., 1998, Vaday and Lider, 2000). In common with the intracellular data, FXR activation 
showed no significant effect on the levels of either MMPs or TIMPs, consistent with a lack of 
FXR-mediated MMP/TIMP secretion. In the present study I demonstrated that the FXR 
ligands CDCA and GW4064 both induced cell death in all breast cancer cells, albeit to 
different extents for each cell line, and the effect of FXR activation on cell viability was more 
pronounced in serum-free conditions. Two possible explanations exist for this observation: 
Firstly, as both CDCA and GW4064 are lipophilic (LogP 3.01 and 9.17, respectively), it is 
likely that a significant proportion is sequestered within serum, reducing the effective 
concentration that cells are exposed to (Rowland et al., 2008). Second, the maintenance of 
cells in serum-free medium tends to produce a less robust phenotype, probably due to the lack 
of key factors such as cytokines that are present in serum (Allegra and Lippman, 1978, 
Hammond and Fry, 1992, Fernandez-Bertolin et al., 2011). In general, GW4064 was more 
potent at causing a reduction in cell viability than CDCA. This is consistent with the reported 
affinities of the two compounds for FXR, with Kd values of 0.01μM and 50μM for GW6064 
and CDCA, respectively (Maloney et al., 2000, Yong et al., 2001). With regard to cell-type 
specificity, there was no significant difference in the IC50 values derived in serum-free 
medium for any of the cell lines: for GW4064 these were 1μM, 3μM, 2.3μM, and 3.5μM for 
MCF-7, MDA-MB-231, MDA-MB-468, and MCF-10A, respectively; for CDCA these were 
196μM, 196μM, and 93μM for MCF-7, MDA-MB-468, and MCF-10A, respectively. For 
MDA-MB-231, it was not possible to generate a robust dose response curve. 
These data are in agreement with the findings of Baker et al., who showed that CDCA had an 
inhibitory effect on MCF-7 cell growth (Baker et al., 1992). This work was expanded by 
Swales et al, who reported that CDCA and GW4064 inhibited cell growth in both MDA-MB-
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468 and MCF7 cell lines (Swales et al., 2006). To further demonstrate that this action may be 
through the activation of FXR, the same group used the secondary bile acid Glycol-CDCA, 
which is well known not to activate FXR. In this case, there was no significant inhibition of 
cell growth of either MDA-MB-468 or MCF-7 cell lines (Swales et al., 2006). Finally, the 
data presented in this thesis is consistent with results published in a study by Giordano et al., 
which showed that activation of FXR by either CDCA or GW4064 decreased MCF-7 cell 
survival by MTT assay. Interestingly, this effect was more pronounced in tamoxifen-resistant 
MCF-7 breast cancer cells (MCF7TR), although the mechanistic explanation for this is not 
clear (Giordano et al., 2011). In this study, Giordano et al., also examined the effect of CDCA 
and GW4064 on MCF-10A cells, concluding that there was no inhibitory effect on MCF10A 
cells (Giordano et al., 2011). While this seems to conflict with the results published here, 
possible reasons for the discrepancy can be put forward. First, the experiments here were 
carried out under both serum and serum free conditions, with marked differences observed; 
Giordano et al. only used serum-containing medium; our findings in presence of serum 
showed no cell death in 48 hours, in this case our results will be consistent with their 
findings. Furthermore, within 72 hours GW4064 developed cell proliferation. Second, in the 
current study higher concentrations of both ligands were used, with maximal concentrations 
of 300μM (CDCA) and 30μM (GW4064) compared to 100μM and 10μM in the Giordano 
study. Third, it clearly established that phenotypic drift can occur in cell lines, resulting in 
significant heterogeneity in a single cell type across different laboratories. As such, the 
difference in MCF-10A cell line response to FXR activation may be due to such phenotypic 
drift. We have established that all cell lines used expressed FXR protein and that this was 
functional (Lisa Mohan, pers comm).  
A single report is in opposition to the findings described above, where Journe et al. 
demonstrated that exposure of MCF-7 cells to CDCA increased the MCF7 cell proliferation 
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in steroid free media (Journe et al., 2008), and had no effect in MDA-MB-231 breast cancer 
cells. Finally, Silva et al. demonstrated increased survival of MDA-MB-231 cells following 
exposure to the secondary bile acid deoxy-cholate (Silva et al., 2006), although its role as an 
FXR agonist is unclear (Xu et al., 2002, Lefebvre et al., 2009). These two observations 
associating FXR with cancer cell survival must be weighed against the larger data that 
suggests FXR activation acts to decrease cell viability. However, it is important to remember 
the controversy in this area and to leave open the possibility that FXR agonists could act to 
both promote and reduce cell viability in a context-dependent manner.  
In summary, the fact that our findings on the decrease in MCF-7 cell viability elicited by 
FXR ligands are consistent with the bulk of the existing literature provides confidence in the 
novel description of the effects of these ligands on other breast cancer cell lines. FXR has 
been shown to be expressed in breast tumours (Swales et al., 2006), and its expression level 
appears to positively correlate with the proliferative capacity of these tumours (Journe et al., 
2009). 
As noted above, the role of FXR expression in non-classical tissues such as the breast is an 
area of debate. Other non-classical tissues that express significant levels of FXR are the 
vasculature and the testis, and it is interesting to note that CDCA and GW4064 also 
stimulated death of rat aortic smooth muscle cells (RASMCs), as measured by MTT assay (Li 
et al., 2007), while in a Leydig cell line (R2C) CDCA had an anti-proliferative effect 
(Catalano et al., 2010).  
Taken together this would suggest that FXR agonists could represent a novel class of 
chemotherapeutics, and that these would be most effective against aggressive tumours. 
However, for such a potential to be translated it is important to take into account all possible 
actions of FXR agonist, such that both positive and negative effects can be assessed. Given 
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the suggestion in some studies that FXR activation may be pro-proliferative, it is important to 
examine the potential for FXR agonists to promote tumour invasion and metastasis.     
To examine the potential FXR activation in the breast cancer cell lines to promote growth and 
invasion, aspects of this biological phenotype were studied next. Levels of the ECM-
remodelling enzymes the MMPs, plus their regulators the TIMPs, were measured at 
transcript, protein and activity level in this chapter, with cellular phenotype assays described 
in Chapter 4. The work described here focuses on MMP-2 and -9, as recent evidence 
implicates them directly in breast cancer initiation and metastasis (Singer et al., 2002, Shen et 
al., 2010). 
Under basal conditions, both MCF-7 and MDA-MB-468 cells had detectable levels of MMP-
9 at both the transcript and protein levels. Likewise, transcript and protein for MMP-2 was 
detectable in MDA-MB-468 cells under basal conditions; however, only MMP-2 
immunoreactive bands were detected from western blotting of MCF-7 protein extracts with 
no MMP-2 transcripts being detected. The discrepancy between transcript and protein 
expression maybe explained by the relatively low transcript levels, certainly below the limit 
of detection for RTPCR. Such a hypothesis is consistent with the findings of Singer et al., 
who did not detect MMP-2 transcripts in MCF-7 cells when using the less sensitive RNase 
protection assay (Singer et al., 2002). In a study using semi-quantitative PCR, transcripts for 
MMP-2 and MMP-9 were detected in MCF-7 and MDA-MB-231 cell lines (Figueira et al., 
2009). Transcript levels in the non-invasive MCF-7 cell line were at the limit of detection, 
while transcript levels in the invasive MDA-MB-231 cell line were higher. Similarly, 
Kousidou et al. reported higher expression of MMP-9 transcripts in both MCF-7 and MDA-
MB-231 breast cancer cell compared to MMP-2, with MMP-2 transcripts being at the limit of 
detection; they also reported that MMP-9 transcript levels were higher in the more invasive 
cell line, consistent with the current study (Kousidou et al., 2004). Within the clinical setting, 
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a similar pattern is also seen, with Wu et al reporting a correlation between MMP-9 transcript 
level and lymph node metastasis in 41 breast cancer specimens (Wu et al., 2014).  
Exposure of either MCF-7 or MDA-MB-468 cells to CDCA (30μM) or GW4064 (3μM) for 
24 hours did not cause any significant increases in either MMP-2 or MMP-9 at either the 
transcript or protein level. In the literature, not a lot of work has been done to investigate the 
effect of FXR activation on MMP expression, with only one study reporting their effect in 
vascular smooth muscle cells (Li et al., 2007). Li et al., reported that treatment with the FXR 
ligands GW4064 and 6ECDCA inhibited the transcript level and enzyme activity of both 
MMP-2 and MMP-9. A possible explanation for the discrepancy between these findings and 
those presented in the current work is the presence of tissue-specific modulatory factors, such 
that the effect of FXR agonists is different between tissues.  
An important aspect of MMP biology is that their site of action is extracellular, as they are 
required for ECM-remodelling (Woessner, 1991, Nagase and Woessner, 1999). Hence, their 
secretion from the cell is as important, if not more so, than increases in intracellular transcript 
or protein levels in determining their biological functionality. To address this important 
aspect of MMP biology I assessed the concentrations of MMP-2 and MMP-9, as well as their 
inhibitory proteins TIMP-1 and TIMP-2 in conditioned media. To ensure direct comparison 
of results, this conditioned medium was saved from the western blotting experiments for 
MCF-7 and MDA-MB-468. In media conditioned with control MCF-7 or MDA-MB-468 
cells, MMP-2, MMP-9, TIMP-1 and TIMP-2 were all detectable. Roomi et al. used gelatin 
zymography to compare the activity of MMP-2 and MMP-9 secreted from 42 different cell 
lines, including MCF-7 and MDA-MB-231 breast cancer cells (Roomi et al., 2009). They 
observed no secretion of either MMP-2 or MMP-9 in control conditioned media, but high 
levels of MMP-9 secretion following treatment with the phorbol ester PMA. The probable 
explanation for the difference between these two datasets is methodological; Roomi et al used 
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gelatin zymography, while in this study ELISA was used, which can be 10-fold more 
sensitive (Zucker et al., 1994) ; in addition, expression of MMPs has been shown to depend 
on culture conditions (Kousidou et al., 2004). In the clinical setting, MMP-2 and MMP-9 are 
detectable in breast tumours, although the exact expression appears to be dependent upon a 
number of factors, such as AP-2 or HER-2 expression (Pellikainen et al., 2004). The 
expression of TIMPs reported in this work is consistent with the work of Kousidou et al, who 
also reported higher expression of TIMP-1 than TIMP-2 transcripts in MCF-7 and MBA-
MD-231 cells (Kousidou et al., 2004). Exposure of either MCF-7 or MBA-MD-468 cells to 
the FXR ligands CDCA (30μM) or GW4064 (3μM) did not increase TIMP-1 or TIMP-2 
extracellular concentrations, as assessed by ELISA of the conditioned media. The literature 
pertaining to FXR-mediated effects on TIMP concentration is not large, and mainly focussed 
on liver, where FXR agonists have been shown to reduce the expressions of TIMP-1 and 
TIMP-2 by approximately 60% in rat hepatic stellate cells (Fiorucci et al., 2005). Likewise, 
Fiorucci et al. demonstrated an inhibition of TIMP-1 in rat hepatic stellate cells following 
exposure to 6ECDCA in vitro (Fiorucci et al., 2005), while FXR null mice exhibit enhanced 
hepatic levels of TIMPs (20-fold) and increase hepatocarcinogenesis (Liu et al., 2012). 
The reason for the discrepancy between these published works and the data presented in here 
is unclear, but there are a number of possibilities: Firstly, this may reflect a tissue-specific 
response to FXR agonists, modulated by co-regulatory proteins; secondly, the main studies in 
liver have been conducted in rodents, and there may exist a species difference in response, 
although a limited number of human cell line studies argue against this; the choice of ligands 
is often different between studies, which is a potential confounding factor; and, in vivo 
studies require a chronic exposure scenario (greater than 1 week) to achieve modulation of 
TIMP activity, which is beyond the exposure paradigm used here.  
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In summary, the work presented in this chapter confirms the cytotoxic ability of FXR 
activation in breast cancer cell lines, and extends these findings to a wider range of cell lines. 
This raises the possibility of FXR activation being used as an adjunct therapy for treatment of 
breast cancer; however, the lack of selectivity between cell lines with a non-aggressive (i.e. 
MCF-7) and aggressive phenotype (i.e. MDA-MB-231 and MDA-MB-468) suggests that 
such a treatment would be non-specific. Any potential therapeutic benefit must be weighed 
against the potential for increased tumour invasion and migration through activation of 
MMPs, as has been reported in other cell types. The work presented in this chapter provides 
no evidence that FXR agonists can modulate the activity of MMPs, or their regulatory 
TIMPs. This is consistent with a mode of action that would not increase tumour invasion 
and/or migration. However, such biochemical findings must be supported by cellular activity 
assays, which will be examined in the next chapter.  
 
 
 
 
 
 
 
 
 
 
 
 
 109 
 
 
 
 
 
 
 
 
 
 
4 Biological effects of FXR agonists 
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 Introduction 
The metastatic journey is a complicated route that involves communication between the 
cancer cells and the host tissue (Silva et al., 2006). It involves escape of neoplastic cells from 
the primary tumour, then invading the surrounding stoma by degradation of extracellular 
matrix, intravasate, entre the blood system, extravasate, further migration, and finally form 
secondary tumours in the new location (Kim et al., 2014, Sprague et al., 2006).  
There are two predominant theories about the mechanism underlying tumour cell metastasis; 
the cancer stem cell hypothesis (Dalerba et al., 2007, Clarke et al., 2006), and the epithelial-
to-mesenchymal transition (EMT) hypothesis (Thiery, 2002, Berx et al., 2007). In the first 
theory, it is proposed that the initiating-tumour cells possess stem cell-like features, including 
the ability to differentiate and proliferate. As such, they may be responsible for both the 
initiation and growth of the primary tumour, and the ability of the growing tumour to invade 
local tissue and, ultimately, metastasise. The EMT hypothesis proposes that the epithelial 
tumour cells receive signals from the adjacent stoma, providing a signal to differentiate to a 
mesenchymal phenotype; such a phenotype would have the ability to lessen cell-cell 
interactions, invade tissue and metastasise. While often seen as competing theories, the 
demonstration that breast cancer stem cells possess mesenchymal features, suggest that these 
two hypothesises may be complementary (Karnoub et al., 2007, Ben-Porath et al., 2008, Yu 
et al., 2007). Beyond these two, traditional, theories, a recent study has suggested the 
metastatic phenotype emerges through a genetic origin (Schischmanov, 2013). This 
hypothesis suggests that in the primary tumour, a cancer-transformed gene is integrated via a 
virus-vector function into recipient cells in other organs, for instance stem cells or cells in an 
early phase of division. 
The epithelial-mesenchymal transition is a process by which epithelial cancer cells of the 
primary tumour change to a mesenchymal, motile phenotype and then re-epithelialize in 
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order to form a secondary tumour at the new metastatic site (Tomaskovic-Crook et al., 2009, 
Spano et al., 2012, May et al., 2011). The exchange of cancer epithelial cells into 
mesenchymal cells involves dramatic phenotypic changes that comprise cell-cell adhesion 
loss, cell polarity loss, and the gain of migratory and invasive properties (Thiery et al., 2009). 
Within breast tissue it is likely that metastasis occurs through a combination of cancer stem 
cells and EMT, with cancer stem cells already possessing a mesenchymal-like phenotype 
(Karnoub et al., 2007, Ben-Porath et al., 2008, Yu et al., 2007). Thus, it is possible that the 
process of metastasis starts with a cancer stem cell predisposed to metastasise, and utilises 
EMT to convert the tumour cells to an epithelial phenotype once they arrive at their new site.  
Matrix metalloproteinases (MMP) are critical molecules in metastasis, initiating the ECM 
degradation required for tumour growth, disaggregation, and invasion into secondary tumours 
(Deryugina and Quigley, 2006). Consistent with this, numerous studies report that gelatinase 
expression and activity is elevated in a wide range of malignancies, and linked to both 
angiogenesis and tumour invasion/metastasis (Sprague et al., 2006, Roomi et al., 2009). 
Importantly, there are a number of studies that demonstrate that inhibition of MMP prevented 
tumour cell invasion (Deryugina and Quigley, 2006). As such, this is a promising area for 
cancer research in general, and metastatic breast cancer in particular, as this is the clinical 
area that is currently poorly served by therapeutic options.  
In this chapter, the potential role of FXR agonists in controlling MMP activity in breast 
cancer cell lines will be further examined. The findings of the previous chapter demonstrated 
that activation of FXR by its agonists CDCA and GW4064 had no effect on protein and 
mRNA levels of MMP-2, MMP-9 TIMP-1 and TIMP-2. In this chapter, these findings were 
extended by using cellular assays to detect MMP activity and cell proliferation/invasion.   
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 Results  
4.2.1 Measuring the effects of FXR agonists on MMP activity using gelatin 
zymography 
Gelatin zymograpy is powerful tool to measure MMP-2 and -9 activities because of their 
ability to degrade gelatin. In addition, as zymography is an electrophoretic technique it 
separates on size, and is able to differentiate between the 92KDa MMP-9 and the 72KDa 
MMP-2 (Davies et al., 1993). This technique also detects both the active and pro- forms of 
the MMPs i.e the potential total gelatinolytic activity (Williams et al., 2004), which is both 
advantageous (the potential total activity is seen), and disadvantageous (it is not clear if this 
potential will be realised in vivo). In this study, gelatin zymography was used to measure the 
effect of the potent FXR ligand GW4064 on the protease activity of both MMP-2 and -9 in 
breast cancer cell lines as described in section 2.2.2.  
Initially, MMP-2 and MMP-9 recombinant proteins were used to optimise the procedure. 
Different amounts of the MMP-2/ -9 standards in each well were loaded onto the gel (4, 8, 
12, 16, 20, 24, 28µl) and PBS as negative control (this experiment was done four times and 
only the fourth experiment worked). Clear bands for both gelatinases -2 and -9 were obtained 
with different intensity according to the amount of the MMP-2/ -9 standards that were loaded. 
These findings suggested that the gelatin zymography worked (Figure 4.1).  
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Figure 4-1 Zymographic gel image for MMP-2 and -9 standards optimisation. Increasing 
quantities of MMP-2 and -9 standards (1:1 mixture) were loaded into 7.5% polyacrylamide 
gel copolymerized with 0.1% gelatin. After the electrophoresis, the gel was washed with 
2.5% Triton X-100 twice for 15 minutes. The gel was incubated in developing buffer 
overnight at 37oC. The gel was stained with comassie blue for 30 minutes, and then destained 
with comassie destain, and the gel was scanned. The clear bands demonstrate the 
gelatinolytic activity of the MMP-2 and MMP-9, as indicated.  
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Following optimisation, the breast cancer cells line MDA-MB-468 was pre-treated with 0.1% 
DMSO, or various concentrations of GW4064 and CDCA, as indicated, for 24 hours. 
Following this incubation, conditioned medium was removed and gelatin zymography 
undertaken. Unfortunately, only transparent bands were observed only for the standards, but 
not the conditioned media (Figure 4.2). 
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Figure 4-2 Zymographic gel images for MDA-MB-468 treated with CDCA and 
GW4064. Human breast cancer cell line MDA-MB-468 was treated with increasing 
concentrations of either CDCA (0, 10, 30, 100, 300µM) or GW4064 (0, 1, 3, 10, 30µM) for 
24 hours under serum free conditions, culture media obtained was used. Lane 1 to 5 tissue 
culture conditioned media; lane 6 to 8 MMP standards (10, 15, 20µl). No activity in 
conditioned tissue culture media was detected, with only clear bands visible for the positive 
control standards.  
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To further investigate and optimise the zymography, and according to the literature, we tried 
to induce the MMPs expression by treating the breast cancer cells MCF-7 and MDA-MB-468 
with known inducers of MMP activity: IL-1β (Yoyo T.Y. Li et al., 2006), EGF (Kondapaka 
et al., 1997), and PMA . Cells were incubated with IL-1β (10 ng/ml), EGF (10 ng/ml), or 
PMA (4nM) for 24 hours or left untreated as a control in serum free condition. Next, 
zymography was undertaken using the conditioned media collected after treatment, along 
with 15 µl of the MMP standards. As shown in Figure 4.3, once again no MMP activity was 
detected in the conditioned media samples, although the standards demonstrated the assay 
was functioning correctly.  
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Figure 4-3 Zymographic gel image for MCF-7 (A) and MDA-MB-468 (B) treated with 
MMP stimulators. Cells were treated with IL 1beta (10ng/ml), EGF (10ng/ml) or PMA 
(4nM) for 24 hours in serum free media, then conditioned media was used for gelatin 
zymography. Clear bands indicative of MMP activity were detected only for the standards.  
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A potential reason for the lack of activity in the zymography assay using the conditioned 
medium is that it was too dilute; meaning that even with the known inducers the amount of 
MMP tested was insufficient to produce a detectable band. According to Hu and Beeton (Hu 
and Beeton, 2010), concentrators can be used to enhance the sensitivity of the zymography 
assay. This approach was next attempted: 4 ml of conditioned medium was placed into the 
concentrators and centrifuged at 4000xg for 20 minutes. The resultant conditioned media 
should be approximately 40-fold concentrated compared to input. However, the neat 
concentrate appeared to be too viscous to enter the gel correctly, and no bands were seen 
(Figure 4.4A).  
To address this issue, a dilution series from the concentrates was used, ranging from 2-fold to 
20-fold diluted. While clear bands could be seen from the standards, the conditioned medium 
failed to produce robust bands (Figure 4.4B). While there was some suggestion that this 
technique might yield results with continued optimisation, for reasons of time an alternate 
approach was investigated. 
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Figure 4-4 Zymographic gel image for MDA-MB-468 and MCF-7 concentrated media. 
A concentrator was used to concentrate the conditioned media, and then gelatin zymography 
undertaken to detect MMP activity. (A) 40x concentrate, plus ultrafiltrate and original media 
sample. (B) Dilution series (2x to 20x) of concentrate. In both cases MMP-2/-9 standards 
were run to indicated expected position of zymography band. 
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4.2.2 Measuring the effects of FXR agonists on MMP activity using cleavage 
assay  
Initially, gelatin zymography was undertaken to assess the effect of FXR ligands on the 
activity of MMPs, but consistent results were not produced. The most likely cause for this 
was the dilution factor inherent to collecting conditioned medium, and hence a more sensitive 
assay was undertaken. A cleavage assay using a specific MMP-2/-9 fluorescent substrate was 
undertaken, as described in 2.2.3, in line with the protocol of Nilsson et al (Nilsson et al., 
2007). The assay has the advantage over zymography that it is more sensitive, but the 
disadvantage that only MMP activity in general can be detected, and MMP-2 and MMP-9 
specific activity cannot be distinguished. As depicted in Figure 4.5, results indicated an 
increase in MMP activity in MDA-MB-468 and MDA-MB-231 cells exposed to GW4064, 
but only at the highest dose tested in both cell lines. There was no effect of CDCA treatment 
in either cell line. No increase in MMP activity was detected in MCF-7 cells exposed to 
either GW4064 or CDCA (Figure 4.5). 
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Figure 4-5 Measuring MMP-2/-9 activities in breast cancer cell lines by cleavage assay. 
A fluorescent substrate was used to assess MMP-2 and -9 activities in serum free conditioned 
media for MCF7, MDA-MB-231and MDA-MB-468 exposed to vehicle control and FXR 
ligands CDCA and GW4064 for 48h. Fluorescence was measured at Ex: 280 nm and Em: 405 
nm. Mean ± SEM, MCF-7 (n=6), MDA-MB-231 (n=8), MDA-MB-468 (n=6). ** p<0.01, 
***p<0.001 compared to control by repeated measures one-way ANOVA (Bonferroni’s 
multiple comparisons test). Parametric statistical analysis was selected because there no 
evidence in the data to indicate Gaussion distribution could not be assumed, majority data 
points are within 1 standard deviation of the mean.  
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These data suggest that GW4064 at high concentrations may activate MMP activity, which is 
at odds with the previous findings that GW4064 didn’t up-regulate the protein and mRNA 
levels of the MMP-2 and MMP-9. Such a discrepancy may reflect a post-translational 
modification, which would only be detected in the activity, which would be of biological 
interest. However, the fact that the effect was only seen at the top concentration, and with 
significant associated error, we decided to use a positive control to optimise the assay and 
ascertain that it was working properly. In order to fulfil this, we used recombinant MMP-2 
and MMP-9 with the fluorescent MMP-9/MMP-1 substrate. The findings showed that MMP 
activity was seen barely at the level of detection using two separate fluorimeters (Figure 4.6). 
On this basis, it is possible that the variable readings seen at the highest concentration of 
GW4064 in MDA-MB-468 and MDA-MB-231 cells was an artefact rather than a true 
positive. Even if the reading was true, at the concentration of GW4064 use it is unclear if the 
effect would have been due to selective activation of FXR, or off-target effects due to the 
high drug concentration (several orders of magnitude above the reported Kd). 
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Figure 4-6 Positive controls for cleavage assay. A cleavage assay was carried out using a 
MMP9/1 flourgenic substrate mixed with serial dilutions of recombinant MMP-9 protein 
(undiluted, 1/10, 1/100, 1/1000, 1/10000 v/v), or a 1:1 mixture of MMP-2/-9 recombinant 
proteins (same dilutions). Fresh medium as a negative control. Fluorescence was measured at 
Ex: 355 nm and Em: 460 nm.  
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4.2.3 Measuring the effects of FXR agonists on breast cancer and normal cells 
migration by transwell migration assay 
The data presented above are consistent with the fact that FXR activation does not cause 
activation of MMPs, which would suggest that there is no positive or negative effect on 
metastatic potential. However, to further examine this potential, cell assays were undertaken 
to examine the impact of FXR activation of cell migration. As migration is the first step for 
cancer cells to invade and metastasize, assessing motility of cancer cells is a critical step in 
studying the mechanism of cancer cell metastasis and invasion (Chen and Nalbantoglu, 
2014). 
The migratory potential of breast cancer (MCF-7, MDA-MB-468 and MDA-MB-231) and 
normal breast (MCF-10A) cell lines was assessed by transwell migration assay as described 
in section 2.2.1.6. Cells were left untreated or pre-treated with the FXR agonists GW4064 
(3µM) and CDCA (30µM) for one hour prior addition to transwells and incubation for 72 
hours. Where cells were pre-treated with FXR agonists, the treatment was continued 
throughout the incubation period. All cell lines demonstrated some migration into the 
receptor reservoir: this was minimal for MCF-7 cells (control mean migration 6.5x104 
cells/ml) and maximal with MDA-MB-231 cells (control mean migration 50x104 cells/ml). 
However, the FXR ligands GW4064 and CDCA had no significant impact on migration of 
any of the cell lines tested (Figure 4.7).  
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Figure 4-7 FXR ligands have no effect on migration of breast cancer & normal cell lines. 
Cells suspensions (1 × 106 cells/ml) were prepared in serum free media and then treated with 
FXR agonists to a final concentration 30µM CDCA and  3µM GW4064 and incubated for an 
hour, and then were seeded to upper chambers. Media with serum added in the lower 
chambers. Chambers were incubated for 72 hours at 37°C. Migrated cells on the underside of 
the filter were trypsinised and counted using a haemocytometer. Mean ± SEM, n=3 in 
duplicates, and data analysis was performed by Friedman test with Dunn’s multiple 
comparisons test to compare treatment groups to control. For MDA-MB-231, MDA-MB-468 
and MCF10A, over 68% of values were within 1 standard deviation of the mean and over 
95% of values were within 2 standard deviations of the mean indicating Gaussian distribution 
can be assumed. However for MCF7 only 50% of values were within 1 standard deviation of 
the mean, indicating Gaussian distribution could not be assumed and so non parametric 
statistical analysis was selected.  
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 Measuring the effects of FXR agonists on breast cancer and normal 
cells migration by scratch wound healing assay 
To complement the results of the transwell migration assay, a scratch wound healing assay 
was performed for all breast cancer cell lines (MCF-7, MDA-MB-231, and MDA-MB-468), 
and the normal breast cell lines MCF10A. The wound healing assay is a technique that 
measures cell migration in vitro by creating a gap or ‘wound’ in a monolayer of cultured cells 
followed by capturing  images at different time points to calculate the gap closure (Rodriguez 
et al., 2005). 
Cells were treated with insulin-like growth factor 1 (IGF-1) (10 ng/ml) as a positive control 
to induce migration (Roussos et al., 2011, Mezi et al., 2012), or with the FXR agonists CDCA 
(30µM) and GW4064 (3µM), or vehicle control (0.1% DMSO). Wound healing was allowed 
to proceed for 24 hours for breast cancer cells and 16 hours for normal breast cells MCF10A. 
Images were then captured at 0-24 h and analysed using the software program T-scratch. 
In MCF-7, our findings suggest that treatment with FXR agonists CDCA and GW4064 had 
only minimal impact on migration when compared to vehicle-treated cells (Figure 4.8). In 
addition, the degree of wound closing was minimal, consistent with the low rate of migration 
observed in the transwell assay. The cell line with the most migration according to the 
transwell assay was MDA-MB-231, and an increased rate of migration was also observed in 
the wound healing assay. By contrast with MCF-7 cells, all treatments caused a significant 
increase in wound closure in MDA-MB-231 cells with GW4064 having the largest effect 
(Figure 4.9).   
In MDA-MB-468, preliminary results suggest that FXR agonists and IGF-1 slightly increased 
the migration compared to the untreated cells (Figure 4.10). However, the experiment was 
done only once, and hence no statistical analysis can be undertaken to confirm the effect of 
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FXR agonists on wound closure. Lastly, in the normal breast cell line MCF-10A, a small 
decrease in migration compared to untreated cells was observed, although this did not reach 
statistical significance (Figure 4.11). 
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Figure 4-8 Effect of FXR agonists on MCF-7 migration assessed by in vitro wound 
healing assay. Cells (5x105 cells/ml) were seeded into culture-insert of µ-Dish35mm, low (ibidi), 
and grown to confluence. The wound was created by removing the ibidi inserts champers. 
Cells were treated with IGF-1 (10 ng/ml) as a positive control, and also treated with DMSO 
(0.1%), and FXR agonists GW4064 (3µM), CDCA (30µM) and cultured for 24 hours. To 
assess the gap closure images were captured at 0 and 24 hours using inverted microscope at 
10x magnification. The wound closure was calculated using T-scratch software. Wound 
healing assay experiments were performed in three independent experimental repeats (n=3), 
Mean ± SEM compared to control by repeated measures one-way ANOVA (Bonferroni’s 
multiple comparisons test). Parametric statistical analysis was selected because there no 
evidence in the data to indicate Gaussion distribution could not be assumed, all data points 
are within 1 standard deviation of the mean.  
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Figure 4-9 Effect of FXR agonists on MDA-MB-231 migration assessed by in vitro 
wound healing assay. Cells (5x105 cells/ml) were seeded into culture-insert of µ-Dish35mm, 
low (ibidi), and grown to confluence. The wound was created by removing the ibidi inserts 
champers. Cells were treated with IGF-1 (10 ng/ml) as a positive control, and also treated 
with DMSO (0.1%), and FXR agonists GW4064 (3µM) and CDCA (30µM) and cultured for 
24 hours. To assess the gap closure images were captured at 0 and 24 hours using inverted 
microscope at 10x magnification. The wound closure was calculated using Tscratch software. 
Wound healing assay experiments were performed in three independent experimental repeats 
(n=3), Mean ± SEM compared to control by repeated measures one-way ANOVA 
(Bonferroni’s multiple comparisons test). Parametric statistical analysis was selected because 
there no evidence in the data to indicate Gaussion distribution could not be assumed, all data 
points are within 1 standard deviation of the mean.  
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Figure 4-10 Effect of FXR agonists on MDA-MB-468 migration assessed by in vitro 
wound healing assay. Cells (5x105 cells/ml) were seeded into culture-insert of µ-Dish35mm, 
low (ibidi), and grown to confluence. The wound was created by removing the ibidi inserts 
champers. Cells were treated with IGF-1 (10 ng/ml) as a positive control, and also treated 
with DMSO (0.1%), and FXR agonists GW4064 (3µM) and CDCA (30µM) and cultured for 
24 hours. To assess the gap closure images were captured at 0 and 24 hours using inverted 
microscope at 10x magnification. The wound closure was calculated using Tscratch software. 
(n=1). 
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Figure 4-11 Effect of FXR agonists on MCF10A migration assessed by in vitro wound 
healing assay. Cells (5x105 cells/ml) were seeded into culture-insert of µ-Dish35mm, low (ibidi), 
and grown to confluence. The wound was created by removing the ibidi inserts champers. 
Cells were treated with IGF-1 (10 ng/ml) as a positive control, and also treated with DMSO 
(0.1%), and FXR agonists GW4064 (3µM) and CDCA (30µM) and cultured for 16 hours. To 
assess the gap closure images were captured at 0 and 16 hours using inverted microscope at 
10x magnification. The wound closure was calculated using Tscratch software. Wound 
healing assay experiments were performed in three independent experimental repeats (n=3) 
Mean ± SEM compared to control by repeated measures one-way ANOVA (Bonferroni’s 
multiple comparisons test). Parametric statistical analysis was selected because there no 
evidence in the data to indicate Gaussion distribution could not be assumed, all data points 
are within 1 standard deviation of the mean.  
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 Discussion 
The aim of this study was to determine whether FXR activation plays a role in regulation of 
MMP activity, a key drive in tumour metastasis. Understanding this relationship is important 
due to the potential for FXR agonists as chemotherapeutic agents. As previously discussed, 
FXR is highly expressed in breast tumours (Swales et al., 2006), and activation of FXR in 
breast cell lines is cytotoxic. Hence, a role of FXR activation in the targeted destruction of 
breast tumours can be hypothesised. However, successful tumour treatment must encompass 
both destruction of existing tumour cells and prevention of tumour invasion and metastasis. It 
is therefore logical to examine the role that FXR has in metastasis.  
In this study we investigated the role of FXR agonists GW4064 and CDCA on the expression 
and the activity of the MMP-2 and -9 in breast cancer MCF-7 (ER+) and MDA-MB-468 and 
MDA-MB-321 (basal-like and mesenchymal-like triple negative breast cancer cells (TNBC), 
respectively, MCF10A (normal) cell lines as models system. The MCF10A cell line is non-
invasive (Capecci and Forgac, 2013). MCF-7 and MDA-MB-468 cell lines are reported to 
exhibit a low invasive phenotype (Zajchowski et al., 2001); MDA-MB-231 exhibits an 
aggressive, invasive phenotype (Zajchowski et al., 2001). 
Gelatin zymography and MMP substrate cleavage assay both failed to detect any MMP 
activity in conditioned medium in these studies. This is in contrast to a number of other 
studies where MMP activity was measured in breast cancer cell line-conditioned medium 
using these techniques (Azzam et al., 1993, Nilsson et al., 2007).   
Gelatin zymography is a technique by which activity of MMP is measured by copolymerizing 
gelatin into gel electrophoresis. When there is activity, clear bands appear in the gel after 
staining (Davies et al., 1993). The most likely explanation for failure of this technique is that 
the MMP concentration in conditioned medium was too low to be detected by this technique. 
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This is supported by the fact that the positive control (recombinant MMP-2/-9) produced 
clear bands on the gel, demonstrating that the technique was working. To address this issue, 
column concentrators were tried. While this produced some very weak bands, suggesting that 
MMP activity was present in the conditioned medium, the bands were too weak for robust 
analysis. Increased incubation time of the cells with FXR ligands and the MMP stimulators 
may have increased the MMP activity in cultured medium, allowing increased detection 
(Liotta and Stetler-Stevenson, 1990). An alternative approach might have been to pre-treat 
the cells with a mixture of insulin-transferrin-selenium for 20 hours prior to drug exposure, as 
these chemicals have been shown to be important for optimal growth and performance of 
zymography under serum free conditions (Agapova et al., 2001). However, due to time 
restrictions it was not possible to continue to optimise the zymography, and an alternative 
technique was sought. 
With regard to the MMP substrate cleavage assay, one possible explanation for the failure is 
interference from other medium components. In the work of Nilsson et al (Nilsson et al., 
2007), MCF-7 and MDA-MB-231 cell lines were used and MMP activity detected in 
conditioned medium without phenol red. Removal of phenol red is common practice in many 
flourometric assays to remove the potential for interference. Meaney and McGuffin, have 
previously examined the fluorometric characteristics of phenol red, determining excitation 
and emission wavelengths of 325nm and 368nm, respectively, as shown in Figure 4.12 
(Meaney and McGuffin, 2008).  
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Figure 4-8 Characterisation of phenol red in Meaney and Mcguffin, 2008 study. 
Normalized excitation (black) and emission (grey) spectra for phenol red (Meaney and 
McGuffin, 2008).  
 
Two substrates were used for the cleavage assay, with λ excitation and λ emission of 280 and 
405 nm and 355 and 460 nm, respectively. While the first substrate may have been subject to 
phenol red interference, the second substrate should have been unaffected, and hence this is 
unlikely to be the problem in this case. 
An alternative potential explanation is that MMPs need a specific temperature to be active 
and cleave their substrates (Apostolidou et al., 2012). While we undertook both cleavage 
assays in accordance with standard protocols, it is possible that laboratory temperature may 
have affected the results observed.   
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Evidence for the role of FXR in MMP regulation is limited, but a study by Das et al showed 
that when FXR was activated by CDCA or 6ECDCA, SHP was up-regulated. SHP acts as a 
transcriptional repressor, and can prevent activity of the SP2/KLF6 repression complex, 
which normally switches off the MMP-9 gene by binding to MMP-9 promoter. Hence, this 
disruption leads to switching on of the MMP-9 gene, which induced blood outgrowth and 
endothelial cell motility (Das et al., 2006). In a follow up study Das et al also demonstrated 
that FXR activation by CDCA increased the endothelial cell motility through regulation of 
FAK and MMP-9. Focal adhesion kinase (FAK) is an important molecule in signalling 
pathways that cause cell migration (Das et al., 2009).  
While neither the zymography or substrate cleavage assay produced robust results, migration 
assays (transwell and wound healing) were successful. Transwell migration assays were 
carried out to examine the effect of FXR ligands GW4064 and CDCA (3 and 30 µM 
respectively) on the migration of breast cancer (MCF-7, MDA-MB-231, MDA-MB-248) and 
normal (MCF10A) cell lines. As expected, the background level of migration varied 
considerably between the cell lines, being lowest for MCF10A and MCF-7 cell lines and 
highest for MDA-MB-231 cells. This is consistent with their known phenotypes, with 
MCF10A and MCF-7 cell lines having a low migratory potential, while MDA-MB-231 cells 
were derived from an aggressive tumour and possess a highly migratory phenotype 
(Zajchowski et al., 2001). Activation of FXR by either ligand had no significant impact on 
migration for any of the cell lines tested. Previous work by Lee et al has shown that GW4064 
(1µM) induced invasion and migration of pancreatic cancer by transwell migration assay 
(Lee et al., 2011), and this would have been a useful positive control to confirm the negative 
impact of the FXR agonists in breast cancer cell lines. Our data suggest that FXR is neither 
pro- or anti-metastatic in breast cancer cell lines, which is in contrast to the work of Silva et 
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al, who showed that FXR activation by deoxycholate (DC) induced MDA-MB-231 breast 
cancer cell migration and metastasis (Silva et al., 2006). 
The existing literature is contradictory on the effect of FXR activation on metastatic potential. 
For example, Debruyne et al demonstrated that the bile acids CDCA, lithocholic acid (LCA), 
colic acid (CA) and deoxycholic acid (DCA) (also called deoxycholate) stimulated the 
invasion of colorectal cancer cell lines PCmsrc and HCT-8/E11 (Debruyne et al., 2002). 
Similarly, work by Silva et al and Krishnamurthy linked FXR activation by deoxycholate to 
increased migration in MDA-MB-231 and 4T1 cell lines (Silva et al., 2006, Krishnamurthy et 
al., 2008). In contrast, studies have shown that the FXR agonists GW4064 and 6ECDCA 
down-regulated migration of vascular smooth muscle cells (Li et al., 2007). Moreover, 
another study highlighted that down regulation of FXR by miR-421 promoted the 
proliferation and the migration of hepatocellular carcinoma cells (Zhang et al., 2012). This 
suggests that the impact of FXR activation on cell migration is complex, and most likely cell-
type specific. 
Consistent with the transwell migration assay, all cell lines tested showed minimal response 
to FXR ligands in the wound healing assay. The only cell line where there was a potential 
alteration in migration was the MDA-MB-231 cell line, where GW4064 and CDCA increased 
wound healing to the same degree as seen with the positive control (IGF-1). MDA-MB-231 
has been categorised as a highly invasive cell line, compared to the weakly invasive MCF-7 
and MDA-MB-468 cell lines (Zajchowski et al., 2001). Previously, Fukase et al demonstrated 
that CDCA and LCA induced migration in Hep3B hepatocellular carcinoma cells by the 
wound healing assay; Hep3B is a cell line with low invasive potential (Fukase et al., 2008, Ip 
et al., 2007). 
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These studies altogether suggest that effect of FXR on the migration is highly dependent on 
the cell- or tissue- type, and potentially the ligand used. However, with regard to breast 
cancer the data presented herein is reasonably reassuring. It appears that activation of FXR is 
unlikely to promote tumour invasion, although the potential for enhanced invasion in already 
aggressive tumours is an area that requires further examination. 
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5 Discussion 
The current study examined the hypothesis that FXR is a novel therapeutic target against 
breast cancer progression and metastasis. FXR is a member of ligand dependant transcription 
factors nuclear receptor superfamily (Makishima et al., 1999, Parks et al., 1999, Wang et al., 
1999), and has been demonstrated to play a potential role in the progression of a number of 
cancers. For example, FXR agonists have been proposed to exhibit positive effects against 
intestinal (Modica et al., 2008), liver (Kim et al., 2007b, Lee et al., 2010) and prostate 
(Kaeding et al., 2008) cancers. These reports would support the development of FXR agonists 
as cancer therapeutics, with a potential target being breast cancer as FXR has been previously 
shown to be over-expressed in some breast tumours (Swales et al., 2006). However, there 
exists a mixed evidence base with respect to the impact of FXR on cell proliferation, with 
reports suggesting it has both positive (Journe et al., 2008, Journe et al., 2009, Lee et al., 
2011) and negative (Chen et al., 2010, Giordano et al., 2011, Deuschle et al., 2012) effects.  
Of particular note is that for breast cancer, evidence exists to support both a pro-proliferative, 
pro-metastatic effect (Journe et al., 2008, Journe et al., 2009) and a protective, non-
proliferative effect (Giordano et al., 2011). For any therapeutic treatment to be successful, it 
must both kill the tumour cells, but also have no positive impact on proliferation and 
metastasis, which could promote tumour progression. It is thus imperative that the potential 
benefits of FXR activation in breast tumour cell lines are fully characterised to assess this as a 
potential therapeutic paradigm.  
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 Cell lines characterisation 
The initial phase of this project was to confirm the cytotoxic ability of FXR agonists, 
extending this characterisation to a range of breast cancer cell lines. The cell lines chosen 
covered a range of phenotypes from low (MCF-7) to high (MDA-MB-231) invasive 
phenotype (Fukase et al., 2008). Both endogenous (CDCA) and synthetic (GW4064) FXR 
ligands were examined using the MTT cell viability assay, under serum-containing and 
serum-free conditions, for 48 and 72 hours exposure. FXR activation caused cell death in all 
cell lines in a concentration- and time-dependant manner. In general, cytotoxicity was more 
marked under serum-free conditions. This effect may be due to the fact that cells in culture 
tend to be more fragile under serum-free conditions, or due to higher intracellular 
concentrations of agonists due to lack of loss through serum sequestration (Kragh-Hansen, 
1981). As expected, GW4064 was a more potent cytotoxin in all cell lines compared to 
CDCA, which is consistent with their differential Kd for FXR activation. Finally, while 
cytotoxicity was seen in all cell lines, differing levels of effect were observed. MCF-7 cells 
were the most resistant to FXR agonist-induced cell death, causing approximately 50% cell 
death at the highest concentration of GW4064 examined following 48h of exposure. In 
contrast, this concentration elicited greater than 75% cell death in the other cell lines.  Due to 
the highly selective nature of GW4064, these effects are likely to be due to activation of 
FXR, rather than an off-target effect. This is supported by the work that demonstrated that 
GW4064 and CDCA killed both MDA-MB-468 and MCF-7 in a concentration-dependant 
manner, but that Glyco-CDCA, which is not an FXR agonist, did not (Swales et al., 2006).  
In addition to the work of Swales et al, this is also consistent with that of Giordano et al, who 
demonstrated that CDCA and GW4064 inhibited the growth of tamoxifen-resistant MCF-7 
breast cancer cells (Giordano et al., 2011). Finally, (Baker et al., 1992) reported that CDCA 
inhibited MCF-7 cell growth. However, other studies have shown the opposite effect. For 
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example work undertaken by (Journe et al., 2008) demonstrated that CDCA induced MCF-7 
cell proliferation. In addition, DC was shown to stimulate MDA-MB-231 survival by Silva et 
al. (Silva et al., 2006). These results are at variance with the data presented in this study and 
previous published studies, and suggest that FXR is correlated with tumour progression. 
Based on the published literature, the weight of evidence supports a cytotoxic ability of FXR 
agonists in breast cancer cell lines, although there is still some conflict in the published data. 
The current work therefore extends previous findings through the study of additional cell 
lines of different phenotype, and provides further evidence for the cytotoxic ability of FXR 
agonists in breast cancer. Furthermore, this work suggests that cytotoxicity may be enhanced 
in cells with an invasive phenotype (e.g. MDA-MB-231) compared to non-invasive 
phenotype (e.g. MCF-7). An important conclusion from the published literature is the 
apparently mixed results of FXR agonists achieved in tumour models, with some models 
reporting cytotoxicity and even tumour regression, while other suggest proliferative effects. 
Given this controversy, it was decided to examine further the potential mechanisms by which 
FXR activation might lead to tumour cell proliferation and invasion, undesirable 
characteristics for a therapeutic agent. Previous evidence has suggested that FXR regulates 
the matrix metalloproteinase (MMP) class of proteins, and their endogenous inhibitors, the 
tissue inhibitors of metalloproteinase (TIMPs) (Fiorucci et al., 2005, Das et al., 2009). MMPs 
are endopeptidases that are required to break down the extra cellular matrix during cell 
migration, and are hence their dysregulation is thought to be key for the invasive/metastatic 
phenotype of many tumours (Sato et al., 1994). Further studies showed that MMP-2 and 
MMP-9 are highly expressed in breast cancers, and are involved in invasion and metastasis 
(Kondapaka et al., 1997). Therefore I next explored whether FXR was a regulator of MMP-2 
and -9, which would explain any pro-invasive phenotype caused by FXR agonists. Protein 
extracts were prepared from MCF-7 (non-invasive) and MDA-MB-468 (invasive) cell lines 
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following treatment with CDCA (30µM) and GW4064 (3µM) for 24 hours. FXR activation 
by these two chemicals did not change the protein levels of the MMP-2 and MMP-9 in either 
breast cancer cell line, although the positive control protein SHP was induced (Lu et al., 
2000). To confirm these findings, Real Time PCR was carried out using the same treatment 
paradigm. The findings by qPCR supported the western blotting data, with FXR activation 
having no effect on transcript levels of MMP-2 and MMP-9. In addition, the levels of TIMP-
1 and TIMP-2, negative regulators of MMP-2 and MMP-9 were examined and shown no to 
change. Only limited studies have been undertaken to study the link between FXR and MMP 
activity, and the results from these are contradictory. Yoyo et al, reported that 6ECDCA, a 
synthetic ligand of FXR, decreased both MMP-2 and MMP-9 gene expression in vascular 
smooth muscle cells, and that this correlated with an inhibition of MMP activity by gelatin 
zymography (Yoyo T.Y. Li et al., 2006). In contrast, Das et al. showed that CDCA increased 
MMP-9 mRNA and protein levels in endothelial cells (Das et al., 2009, Das et al., 2006). 
They also showed that FXR activation increased MMP-9 gelatinolytic activity in endothelial 
cells in an FXR-dependent manner (Das et al., 2006). Consistent with this pro-invasive action 
of FXR agonists, Fiorucci et al. demonstrated that 6-ECDCA inhibited TIMP-1 mRNA 
expression and activity through an SHP-dependant mechanism in hepatic stellate cells 
(HSCs) and in vivo (in liver of rats) (Fiorucci et al., 2005). A possible explanation for the 
inconsistency of these findings is that the investigators used various types of tissues, different 
ligands and different exposure paradigms, making a direct comparison difficult. There is no 
reason to doubt the negative impact observed in the current study, and indeed this would be 
consistent with the apparent tissue-specific nature of the FXR-MMP interactions previously 
described. 
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 Biological activity of FXR agonists 
Given the contradictory evidence in the literature regarding the potential proliferative effect 
of FXR agonists, and the interaction between FXR and MMPs, it was logical to look at 
cellular phenotype rather than molecular endpoints. Therefore, I next explored the role of the 
FXR agonists CDCA and GW4064 in regulation of MMP-2 and MMP-9 activity in MCF-7, 
MDA-MB-468 (weakly-invasive), MDA-MB-231 (highly invasive) and MCF-10A (normal) 
breast cell.  
Initially, gelatin zymography was used to investigate the activity of MMPs in the conditioned 
media. However, no activity was detected in my conditioned medium samples, despite the 
detection of gelatinolytic activity with the positive control recombinant MMP-2/9 proteins. 
Therefore, an alternative assay was used, which was a cleavage assay using fluorescent 
MMP-2/9 substrate as an alternative for activity detection, but unfortunately it failed to work 
as well in our lab. The reason for these failures are likely to be technical rather than 
biological, as the response from positive controls and/or standards curves were satisfactory. 
For the gelatin zymography, the most likely reason is one of concentration, with the MMP-
2/9 activity in the conditioned medium being too low for detection by this method. 
Concentration of the samples was hindered by the increased viscosity, meaning that gel 
loading was impaired. For the cleavage assay, both assay temperature (Apostolidou et al., 
2012) and inclusion of phenol red in the medium (Nilsson et al., 2007) may have been 
potential issues. One further area for examination would be the use of Insulin-Transferrin-
Selenium as a pre-treatment, as this has been shown to improve assay performance under 
serum free conditions (Agapova et al., 2001). However, exploration of these failed to solve 
the issues and it was decided to move on to another approach.  
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Rather than assaying MMP activity, I next looked at the migration/proliferative ability of the 
cells. While this had been previously tested to some degree through the MTT assay, there are 
other approaches that are superior for examining this endpoint, especially with regard to 
tumour growth and invasion: transwell migration and wound healing assays. For the transwell 
assay, the findings demonstrated that FXR activation didn’t increase/decrease the migratory 
response of all the breast cancer cell lines tested. To confirm this finding, it would be best to 
include a positive control into the assay such an IGF-1, which was not done. For the wound 
healing assay, once again, there was a minimal impact of FXR activation for the majority of 
cell lines tested. In this case, a response to the positive control IGF-1 was observed, 
increasing the robustness of the results. The only cell line where a positive impact of FXR 
activation on wound healing was observed was MDA-MB-231 cells. It should be noted that 
there is a potential effect in MDA-MB-468 cells, which are also regarded as having a weakly 
invasive phenotype. However, data is only n=1 and hence has to be treated with caution.  
The data produced here were consistent with the work of Silva et al who showed that 
deoxycholate, a secondary bile acid and FXR ligand, promoted the migration of MDA-MB-
231 cells, but had no impact on MCF-7 cells (Silva et al., 2006). In addition, Silva et al 
demonstrated that DC treatment up-regulated gene expression of the protease urokinase-type 
plasminogen activator (uPA), and induced formation of F-actin; both of these are consistent 
with breast cancer migration (Silva et al., 2006). Finally, work with another invasive breast 
cancer cell line (4T1) also supported increased migration mediated through FXR activation. 
(Krishnamurthy et al., 2008). 
Together, the data presented in this thesis and the existing literature are consistent with the 
hypothesis that FXR activation can lead to an increase in breast cancer cell migration, but 
only in those cells that already have an invasive phenotype. This raises an important caveat 
for the role of FXR agonists as potential cancer therapeutics: while they are undoubtedly 
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cytotoxic, it appears that for more aggressive tumours they may exacerbate tumour growth 
and invasion. In such cases, the risk:benefit would, obviously, be negative, while for non-
aggressive tumours it might be positive. Thus, it would appear that any development of FXR 
agonists as cancer chemotherapeutics would also rely on stratification biomarkers to allow 
the identification of the tumour phenotype, targeting therapy towards those cases most likely 
to benefit from treatment.  
It is important to note that the literature reports mixed effects of FXR agonists on migration 
in cell lines from different tissue origins. For example, Lee et al report a positive effect, with 
GW4064 (1µM) stimulating invasion and migration of pancreatic cancer measured by 
transwell migration assay (Lee et al., 2011). Likewise, Debruyne et al demonstrated that the 
bile acids CDCA, lithocholic acid, colic acid and deoxycholic acid promoted colorectal 
cancer invasion in the cancer cell lines PCmsrc and HCT-8/E11 (Debruyne et al., 2002). 
However, other studies have shown that FXR is a migration suppresser: Li et al demonstrated 
that GW4064 and 6ECDCA inhibited migration in vascular smooth muscle cells (Li et al., 
2007), while FXR-mediated down-regulation through promoted proliferation and migration 
of hepatocellular carcinoma cells (Zhang et al., 2012).  
Given the controversy in the literature regarding the impact of FXR agonists on cell 
migration, it is difficult to come to a firm conclusion. For breast cancer, the weight of 
evidence seems to suggest that the effect is dependent on the original cellular phenotype. 
Indeed, this may explain some of the inconsistency seen in cell lines derived from other 
tissues. This inconsistency might indicate a tissue-specific response, or may simply reflect the 
invasive phenotype of the cell lines tested, regardless of their tissue origin. More work is 
needed in this area to delineate the whole-body effects of FXR activation.  
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 Future work 
There are some rational directions for the continuation of the work done in this study. Firstly, 
as my work was all in vitro, I can look at effects of FXR activation in vivo (mouse 
xenografts). Secondly, look at the impact of FXR activation on angiogenesis as well both in 
vitro and in vivo (chicken egg model or xenografts). Third, given the large number of 
reported effects for FXR in the literature, and the apparent tissue-/cell line differences, a 
DNA microarray approach could be used to examine the wider effects of FXR activation in 
vitro. As there have been reports of miRNA involvement in FXR effects, I could look at this. 
Moreover, there have been reports that some of the effects of GW4064 could be FXR-
independent. It would be nice to further investigate this and see if this is (a) true, and (b) 
which effects are FXR dependent and which are not (and the mechanism for the latter). Also I 
could use a combination of GW4064 and breast cancer chemotherapy drugs such as 
doxorubicin and tamoxifen in vitro and in vivo to investigate if it can lower the doses of anti-
cancer drugs. I can re-do the activity assay (gelatin zymography and cleavage assay) avoiding 
this time all the possible reasons that used in this project that caused not getting the proper 
findings. Furthermore, it will be interesting to investigate breast tissue and breast tumour 
tissue. Lastly, I could look at the effects of FXR activation on other MMPs such as MT1-
MMP as it is highly expressed in aggressive breast cancer (Jiang et al., 2006), and also 
investigate other metastasis systems for instance urinary (uPA) or tissue-type (tPA) 
plasminogen activators as these are critical migration factors in breast cancer (Silva et al., 
2006). 
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 Final conclusion  
Previous work has demonstrated that FXR is expressed in breast tissue and that there is 
increased expression in certain breast tumours (Swales et al., 2006). Given the evidence 
presented herein and in the literature, for FXR-mediated cytotoxicity (Giordano et al., 2011, 
Baker et al., 1992, Journe et al., 2008), a potential role for FXR agonists as cancer 
chemotherapeutics can be postulated. However, studies of FXR agonists have produced 
inconsistent data on their ability to promote tumour invasion and drive metastasis. Work 
within this thesis expands upon the current literature for breast cancer in this area, and is 
consistent with the hypothesis that the migratory impact of FXR agonists is set by the original 
phenotype of the cell. Hence, cells with low invasive potential (e.g. MCF-7, MCF-10A) 
demonstrate no enhanced migration, while invasive cell lines (e.g. MDA-MB-231, MDA-
MB-468) do. This raises an important safety issue for the development of FXR agonists as 
cancer chemotherapeutics, as they may actually promote the metastasis of tumours that 
already possess an aggressive phenotype. This further underlines the importance of tumour 
stratification prior to treatment, ensuring that optimal drug cocktail is prescribed.    
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